Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 1 of 73 
    
Terumo Study  No.:   TIS20 18-01 
Version No.    1.4 
Date     29JUL2020  
 
 
 
 
 
 
 
TIS2018 -01:   Cross -SealTM IDE Trial:  Prospective, Multi -Center, Single Arm  
Study of the Cross -SealTM Suture -Mediated Vascular Closure 
Device System  
 
  
 
 
 
SPONSOR:   Terumo Medical Corporation  
265 Davidson Avenue  
Somerset, NJ 08873  
USA 
 
 
 
 
 
 
 
Confidentiality Statement:  
This protocol, its contents, and the information relating to it are the proprietary 
property of Terumo Medical Corporation. All information is to be kept confidential.  
 
 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 2 of 73 
    Clinical Protocol  
 
 
 
Title:  Cross -Seal IDETM Trial:   Prospective, Multi -Center, 
Single Arm Study of the Cross -SealTM Suture -
Mediated Vascular Closure Device System  
  
Study Number:  TIS2018 -01 
 
Investigational  Cross -SealTM Suture -Mediated Vascular Closure  
Device:   Device System (Cross -SealTM System)  
 
Study Type:    Prospective, multi -center, single arm  
 
Version:  1.4 
 
Version Date:  29JUL2020  
 
Sponsor:  Terumo Medical Corporation  
  
  
 
 
 
 
 
 
 
 
 
  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 3 of 73 
 Table of Contents  
 
A. Summary Of Changes  ................................ ................................ ...................  6 
B. Protocol Approval Page  ................................ ................................ .................  7 
C. Study Roles and Responsibilities  ................................ ................................ ... 8 
D. Investigator Approval and Agreement  ................................ ..........................  10 
E. Study Summary  ................................ ................................ ...........................  11 
Sample Size  Determination  ................................ ................................ ................  15 
Primary Efficacy Endpoint  ................................ ................................ ...............  16 
Primary Safety Endpoint  ................................ ................................ ..................  16 
F. List of Abbreviations and Definition of Terms ................................ ...............  18 
1 Background ................................ ................................ ................................ .. 19 
1.1 Need For Large Arteriotomy VCD  ................................ ..........................  20 
1.2 Current Large Arteriotomy VCDs  ................................ ...........................  21 
1.2.1  Clinical Experience With Suture -Based VCDs  ................................ ....... 22 
1.2.2  Advantages of Suture -based VCDs  ................................ .......................  22 
1.3 Cross -SealTM System and Indications For Use  ................................ ...... 23 
1.4 Description of Device  ................................ ................................ .............  23 
1.5 Summary of Clinical Studies  ................................ ................................ .. 26 
1.5.1  Clinical Feasibility (FIH) Study  ................................ ...............................  26 
1.5.2  CE Study  ................................ ................................ ................................  28 
2 Study Design, Sample Size and Duration  ................................ ....................  30 
2.1 Study Design  ................................ ................................ .........................  30 
2.2 Sample Size  ................................ ................................ ...........................  31 
2.3 Study Duration  ................................ ................................ .......................  31 
3 Study Objective, Hypothesis, and Endpoints  ................................ ...............  31 
3.1 Study Objective  ................................ ................................ ......................  31 
3.2 Study Hypothesis  ................................ ................................ ...................  32 
3.3 Endpoints  ................................ ................................ ...............................  32 
3.3.1  Primary Endpoints  ................................ ................................ .................  32 
3.3.2  Secondary Endpoints  ................................ ................................ .............  33 
3.3.3  Exploratory Endpoints  ................................ ................................ ............  35 
4 Study Design  ................................ ................................ ...............................  35 
4.1 Eligibility Criteria  ................................ ................................ ....................  35 
4.2 Subject Enrollment  ................................ ................................ .................  38 
5 Ethics  ................................ ................................ ................................ ...........  38 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 4 of 73 
 5.1 Role of the Sponsor  ................................ ................................ ...............  38 
5.2 Role of Clinical Research Organization  ................................ .................  39 
5.3 Ethics Review  ................................ ................................ ........................  39 
5.4 Ethical Conduct of the Study  ................................ ................................ .. 39 
5.5 Written Informed Consent  ................................ ................................ ...... 39 
5.6 Subject Data Protection  ................................ ................................ .........  40 
5.7 Subject Withdrawal  ................................ ................................ ................  40 
5.8 Discontinuing Subject Participation  ................................ ........................  40 
6 Device Supply Information  ................................ ................................ ...........  41 
6.1 Shipping  ................................ ................................ ................................ . 41 
6.2 Labeling  ................................ ................................ ................................ . 41 
6.3 Storage  ................................ ................................ ................................ .. 41 
6.4 Accountability  ................................ ................................ .........................  41 
6.5 Return of a Malfunctioning/Failed Device  ................................ ..............  42 
7 General Procedures  ................................ ................................ .....................  42 
7.1 Baseline/Pre -Procedure Visit  ................................ ................................ . 42 
7.2 Index Procedure  ................................ ................................ ....................  43 
7.3 Investigational Device Set -up and Preparation  ................................ ...... 47 
7.4 Concomitant Medical Therapy  ................................ ...............................  47 
7.5 Follow -up Procedures  ................................ ................................ ............  47 
7.5.1  Post-Procedure through Hospital Discharge  ................................ ..........  47 
7.5.2  30 Day Follow -Up (30 ¬± 7 days)  ................................ ............................  48 
7.5.3  60 Day Follow -Up (60 days ¬± 14 days)  ................................ ..................  48 
7.6 Clinical Data Collection  ................................ ................................ ..........  49 
8 Adverse Events  ................................ ................................ ............................  49 
8.1 Definitions  ................................ ................................ ..............................  50 
8.2 Potential Adverse Events (AEs)  ................................ .............................  51 
8.3 Follow -up of Adverse Events  ................................ ................................ . 52 
8.4 Causality Rating  ................................ ................................ .....................  52 
8.5 Severity of Adverse Events  ................................ ................................ .... 53 
8.6 Events Requiring Expedited Reporting  ................................ ..................  53 
8.6.1  Expedited Events include: ................................ ................................ ...... 54 
8.7 Clinical Events Committee (CEC)  ................................ ..........................  55 
8.8 Data and Safety Monitoring Board (DSMB)  ................................ ...........  55 
9 Risk Assessment  ................................ ................................ .........................  56 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 5 of 73 
 9.1 Risk Management Procedure  ................................ ................................  56 
9.2 Potential Benefits  ................................ ................................ ...................  57 
10 Centers for Medicare and Medicaid Services (CMS) Reimbursement  .........  57 
11 Monitoring  ................................ ................................ ................................ .... 58 
12 Image Analysis  ................................ ................................ ............................  59 
13 Device Failure and Malfunction  ................................ ................................ .... 59 
14 Statistical Methods  ................................ ................................ .......................  60 
14.1  Sample Size  Determination  ................................ ................................ ... 60 
14.1.1  Primary Efficacy Endpoint  ................................ ...............................  61 
14.1.2  Primary Safety Endpoint  ................................ ................................ .. 62 
14.2  Statistical  Analyses  ................................ ................................ ................  63 
14.2.1  General  Considerations  ................................ ................................ ... 63 
14.2.2  Analysis  Populations  ................................ ................................ ....... 64 
14.2.3  Poolability  Analyses  ................................ ................................ ........  65 
14.2.4  Handling of Missing  Data  ................................ ................................  65 
14.2.5  Imputation for Endpoints  ................................ ................................ . 66 
14.2.6  Sensitivity Analyses ................................ ................................ .........  66 
14.2.7  Imputation for Dates  ................................ ................................ ........  66 
14.2.8  Subject  Disposition  ................................ ................................ ..........  67 
14.2.9  Demographics and Baseline  Characteristics  ................................ ... 67 
14.2.10  Analysis of Study  Endpoints  ................................ ............................  67 
14.2.11  Subgroup  Analyses  ................................ ................................ .........  68 
14.2.12  Interim  Analyses  ................................ ................................ ..............  68 
14.2.13  Protocol  Deviations  ................................ ................................ .........  69 
14.2.14  Additional Changes to Planned  Analyses  ................................ ........  69 
15 Reporting  ................................ ................................ ................................ ..... 69 
Appendix 1  References  ................................ ................................ ...................  70 
 
  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 6 of 73 
 A.  Summary Of Changes  
 
CIP 
Version  CIP Date  Description of change and rationale  
1.0 01 Jun 2018 Initial Release  
1.1 14 Aug 2018  ‚Ä¢ Eligibility criteria updated  
‚Ä¢ Study Endpoints updated  
‚Ä¢ Abbreviations and Definitions of Terms updated  
‚Ä¢ Baseline visit assessments amended to include laboratory 
requirements and targeted groin exam  
‚Ä¢ General and Procedural sections updated for additional 
requir ements  
‚Ä¢ Schedule of Events Table updated to reflect protocol changes  
‚Ä¢ Concomitant Medication requirements updated regarding 
anticoagulants/anti -platelet use during index procedure  
‚Ä¢ Potential Adverse Events updated  
‚Ä¢ Minor clarification to text  
1.2 27Sep2018  ‚Ä¢ Update to hypotension definition in procedural section  
1.3 30Oct2018  ‚Ä¢ Update to statistical methods  including performance goal for 
primary safety endpoint  
‚Ä¢ Update of images and description for generation 2.2 knot tyer  
‚Ä¢ Minor clarification to text  
1.4 29JUL2020  ‚Ä¢ Change Sponsor address and study personnel update  
‚Ä¢ For consistency across protocol and SAP - Clarified definition 
of ‚Äúadjunctive treatment.‚Äù  
‚Ä¢ Addition of unscheduled visit sand telephone assessment to 
assess safety of patients whose follow up visits were affected 
by COVID -19 
‚Ä¢ Update to statistical analysis  sections to reflect imputation of 
data points and potential use of roll -in subjects if needed  
‚Ä¢ Minor clarification to text  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page Section Intentionally Blank  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 8 of 73 
  
 
 
C. Study Roles and Responsibilities  
 
Principal Investigators:        Prakash Krishnan, MD  
 Mazin Foteh, MD  
 
Medical Monitor:      Mike  Martinelli , MD 
    Terumo Medical Corporation  
 
Sponsor Contact:   Robert Gash  
Director of Clinical Operations  
Terumo Medical Corporation  
265 Davidson Ave nue 
Somerset , NJ 08873  
Phone :  908-914-1045  
 
CRO:      Syntactx  
 
Core Laboratory:   Syntactx  
 
Proprietary Notice:  This document contains mainly unpublished data and is 
the sole property of the Sponsor . Therefore, it is provided 
to you in strict confidence as an investigator, potential 
investigator, or consultant. The information may be 
reviewed by you, your staff, and your institutional review 
board/independent ethics committee. It is understood that 
this information will not be disclosed to other s without 
writte n authorization from the study Sponsor  except to the 
extent necessary to obtain informed consent from those 
persons in whom the investigational device may be 
implanted.  
 
Ethics Statement:  The study will be completed in accordance with applicable 
regulation s and standards to  provide public assurance that 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 9 of 73 
 the rights, safety, and well -being of study  subjects are 
protected, consistent with the principles that have their 
origin in the Declaration of Helsinki.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Page Section Intentionally Blank  
  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 10 of 73 
 D. Investigator Approval and Agreement  
 
PROTOCOL SIGNATURE PAGE  
 
The signature below constitutes the receipt, review and understanding of the protocol 
entitled , ‚ÄúCross -SealTM IDE Trial:  Prospective, Multi -Center, Single Arm  Study of the 
Cross -SealTM Suture -Mediated Vascular Closure Device System  ‚Äù and any attachments, 
and provides the necessary assurances that this study  will be conducted according to all 
stipulations of the signed Clinical Trial Research Agreement (CTR A), protocol, including 
all stat ements regarding confidentiality, and according to local legal and regulatory 
requirements and applicable U.S. federal regulations.    
 
 
 
 
 
___________________________ _____                              _______________________                               
Investigator Signature    Date ( DD/MMM/YYYY ) 
 
 
__________________________________________________________________ ____ 
Investigator Name (please print)  
 
 
______________________________________________________________ ______ __ 
Investigator Institution (please print)  
  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 11 of 73 
 E. Study Summary  
 
Study Design  
This is a prospective, multi -center, single arm, clinical study  to investigate the safety and 
efficacy of the Cross -SealTM System.  
 
Investigational Device  and Indications for Use  
The Cross -SealTM System is indicated for the percutaneous delivery of sutures for 
closing the common femoral artery access site of subject s who have undergone 
interventional catheterization procedures using 8F r to 18F r sheaths.  
 
Target Subject Population  
The target population is comprised of subjects scheduled for elective percutaneous 
intervention with introducer sheath  sizes of 8 -18Fr  and planned percutaneous 
arteriotomy closure. Applicable procedures include Transcatheter Aortic Valve 
Replacement (TAVR ), Endovascular Aneurysm Repair (EVAR) . Thoracic Endovascular 
Aneurysm Repair  (TEVAR)  and Balloon Aortic Valvuloplasty (BAV) . 
 
Study Center(s) and Number of Subjects Planned  
A minimum of 3 sites and u p to 25 sites in the US are expected to participate in the 
study with approximately 100 pivotal subjects enrolled. No more than 15% of the pivotal 
subjects may be enrolled at a single investigational site.  
 
The first 1 -2 subjects enrolled by each investiga tor will be considered roll -in subjects to 
allow for physician experience with the investigational device. A maximum of 3 study 
investigators and 6  roll-in subjects will be permitted at each investigational site.   
 
In total, up to  250 subjects will receive  the investigational device as part of the clinical 
study.  
 
Study Duration  
Study enrollment is expected to occur over a 10 to 12-month  period. Imaging  and follow -
up procedures will continue through 30 days post -procedure. Subjects with an abnormal 
Duplex Ultrasound (DUS) at 30 days will have a repeat DUS at 60 days post -procedure 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 12 of 73 
 (all DUS will be analyzed by an independent core laboratory). The total st udy duration is 
expected to be approximately 24 months . 
 
Note: Due to the COVID -19 pandemic, some patient follow -up visits have been delayed 
greater than 6 months or completely missed; therefore, making data collection extremely 
difficult (e.g., missed D US assessments) to support some of the secondary endpoints. 
To evaluate safety, we have added an unscheduled visit and telephone assessment (if 
needed) to be conducted as soon as possible based on physician and hospital 
regulatory discretion.  
 
Study Objective  
The study objective is to demonstrate the safety and efficacy of the investigational 
device to achieve hemostasis of common femoral artery access site in subjects 
undergoing percutaneous endovascular procedures utilizing 8 -18Fr introducer sheath . 
 
Study Hypothesis  
Safety:  
The freedom from major complications at the target limb access site within 30 days post -
procedure will be greater  than the specified Performance Goal (PG) . 
 
Efficacy:  
Following use of the investigational device , the mean Time -to-Hemostasis (TTH)  will be 
less than the specified P G. 
 
Endpoints  
The f ollowing study endpoints will be evaluated:  
 
Primary Safety Endpoint:  
‚Ä¢ Freedom from major complications of the target limb access site within 30 days 
post-procedure which includes the following:  
 
Major Complications:  
‚Ä¢ Vascular injury attributable to the investigational device that requires surgical 
repair, stent -graft, or balloon angioplasty  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 13 of 73 
 ‚Ä¢ Access site -related bleeding attributable to the investigational device  that 
requi res transfusion  
‚Ä¢ Any new access site -related ipsilateral lower extremity ischemia attributable to 
the investigational device and documented by patient symptoms, physical exam, 
and/or decreased or absent blood flow on lower extremity angiogram  
‚Ä¢ Surgery for ac cess site -related nerve injury attributable to the investigational 
device  
‚Ä¢ Permanent (lasting > 30 days) access site -related nerve injury attributable to the 
investigational device  
‚Ä¢ Access site infection requiring intravenous antibiotics and/or extended 
hosp italization  
 
Primary Efficacy Endpoint :   
‚Ä¢ The mean TTH in the Common Femoral Artery (CFA) of the target limb access 
site with use of the investigational device.  
 
TTH will be evaluated from time of procedural sheath removal to first 
observed cessation of CFA bleeding (excluding cutaneous or 
subcutaneous oozing  at access site ) in the target limb for subjects not 
requiring adjunctive intervention.  
 
If a sheathless sy stem is used during the procedure, TTH will be  
calculated  from final introducer  sheath removal to first observed cessation 
of CFA bleeding (excluding cutaneous or subcutaneous oozing  at access 
site) in the target limb  for subjects not requiring adjunctive intervention . 
 
Adjunctive Intervention is defined as any use of surgical or end ovascular 
intervention OR firm/occlusive manual pressure needed to achieve 
access site hemostasis (light/non -occlusive pressure to control cutaneous 
or subcutaneous oozing at the access site is excluded).  
 
Secondary Safety Endpoints:  
‚Ä¢ The freedom from minor  complications at the t arget limb access site within 30 
days post -procedure including the following:  
 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 14 of 73 
 Minor Complications :  
o Non-treated pseudoaneurysm attributable to the investigational device 
and documented by DUS  
o Pseudoaneurysm attributable to the investigational device and treated 
with ultrasound -guided compression, ultrasound -guided thrombin 
injection. or ultrasound -guided fibrin adhesive injection  
o Non-treated or treated arteriovenous (AV) fistula attributable to the 
investigational device and doc umented by DUS  
o Access site hematoma greater than or equal to 10 cm in diameter, 
attributable to the investigational device, and confirmed by DUS  
o Late (following hospital discharge) access site -related bleeding in target 
limb 
o Lower extremity arterial emboli  attributable to the investigational device  
o Vein thrombosis attributable to the investigational device  
o Transient access site -related nerve injury attributable to the 
investigational device  
o Access site wound dehiscence  
o Access site infection treated with int ramuscular or oral antibiotics  
‚Ä¢ Device Related Complications (DRCs) and procedural complications within 30 
days post -procedure  
‚Ä¢ Evaluation of all Adverse Events (AEs) from time of investigational device 
use within 30 days post -procedure, and through 60 days  post-procedure 
for subject‚Äôs requiring a repeat DUS, including major and minor 
complications  
 
Secondary Efficacy E ndpoints:  
‚Ä¢ Technical Success:  defined as achievement of hemostasis with the 
investigational device without the need for any access -site-related adjunctive 
surgical or endovascular intervention  (target limb only) .  
‚Ä¢ Access site closure success:  defined as technical success  and freedom from 
major complications within 48 hours of the index procedure or hospital discharge, 
whichever occurs first (target limb only) . 
‚Ä¢ Treatment Success:  defined as technical success  and freedom from major 
complications  through 30 days follow -up. 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 15 of 73 
 ‚Ä¢ Subjects requiring adjunctive surgical or endovascular intervention to achieve 
hemostasis of the access site (target limb only) including type of adjunctive 
intervention.  
‚Ä¢ Subjects receiving adjunctive manual compression following use of the 
investigational device to achieve hemostasis of the access site (target limb only).  
o Type of compression applied (light or fi rm, where light compression is 
defined as non -occlusive (i.e., ‚Äúpatent hemostasis‚Äù) allowing distal blood 
flow, and firm compression defined as occlusive prohibiting distal blood 
flow.  
‚Ä¢ Time -to-Ambulation:  defined as elapsed time from final procedural she ath 
removal to time when the subject stands and walks at least 20 feet without 
re-bleeding.  
‚Ä¢ Time -to-Discharge (i.e., time of actual discharge defined as the elapsed time 
between final procedural sheath removal and when the subject is actually 
discharged fr om the hospital)  
‚Ä¢ Occurrence of device failure  as defined in Section 13.0  
 
Exploratory Endpoints:  
‚Ä¢ Time -to-Device -Deployment defined as time of guidewire removal during device 
insertion to time of guidewire reinsertion during device removal, and overall 
procedure time defined as time of first skin nick/incision to achievement of 
hemostasis in the access site (target limb only)  
‚Ä¢ Time -to-Dischargeability (i.e., discharge eligibility defined as the elapsed time 
between final procedural sheath removal and time whe n the subject is medically 
able to be discharged based solely on the assessment of the access site as 
determined by the investigator.  
 
Statistical Methods  
Sample Size  Determination  
The sample size calculations were performed using PASS 2020 Version 20.0.2i.  The 
appendix included the output from the software.  The sample size for the study is 
based on power considerations for the primary effectiveness endpoint. As will be 
described below, this sample size should also provide adequate power for the 
primary safety endpoint.  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 16 of 73 
 Primary Efficacy Endpoint  
The primary effectiveness hypothesis will be tested by comparing the primary 
effectiveness endpoint, mean time -to-hemostasis (TTH), against a performance goal 
(PG) of 15 minutes.  
The comparison to the performance goal will be based on the following statistical 
hypothesis test:  
ùêªùëÇ: ùúáùëáùëáùêª    ‚â• 15 
ùêªùê¥: ùúáùëáùëáùêª    < 15 
where ùúáùëáùëáùêªis the mean time -to-hemostasis in  minutes.  
The test will be based on whether the upper one -sided 97.5% confidence limit (based 
on a t -distribution)ii is less than 15. Assuming similar performance to Perclose 
ProGlide¬Æ, with a mean time -to-hemostasis of 9.8 minutes and a standard deviation 
of 17 minutes the sample sizes for power levels from 80 to 90%  
a Table 1: Primary Efficacy Endpoint Sample Sizes for Various levels of Power  
Power  Sample Size  Maximum Observed Time 
(minutes) and still reject H 0 
80.0%  86 10.8 
81.4%  89 10.9 
82.3%  91 10.9 
83.1%  93 10.9 
84.3%  96 11.0 
85.0%  98 11.1 
Successful rejection of the null hypothesis will mean that the PG has been met.  
 
Primary Safety Endpoint  
The primary safety hypothesis will be tested by comparing the primary safety 
endpoint, freedom from major complications of the target limb access site within 30 
days post -procedure, ag ainst a performance goal.   
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 17 of 73 
 The comparison to the performance goal will be based on the following statistical 
hypothesis test:  
ùêªùëÇ: ùëù ‚â§ 85.2%  
ùêªùê¥: ùëù > 85.2%  
where p is the safety endpoint rate for the test device.  
Assuming similar performance as ProGlide (an event -free rate of 94%), one -sided 
alpha = 0.05, the sample sizes for various levels of power are:  
Table 2: Primary Safety Endpoint Sample Sizes for Various levels of Power  
Power  Sample Size  Minimum # of Event Free 
Patients needed to reject the 
H0 
81.3%  78 72 
85.6%  86 79 
88.3%  95 87 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 18 of 73 
 F. List of Abbreviations and Definition of Terms  
AE: Adverse Event  
ACT:  Activated Clotting Time  
AV: Arteriovenous  
BAV:  Balloon Valvuloplasty  
BMI:  Body Mass Index  
CE: Conformit√© Europ√©ene   
CEC:  Clinical Events Committee  
CFA:  Common Femoral Artery  
CFR:  Code of Federal Regulations  
CIP: Clinical Investigational Plan  
CRO:  Clinical Research Organization  
CTRA:  Clinical Trial Research Agreement  
CVD:  Cardiovascular Disease  
DRC:  Device Related Complication  
DSMB:  Data Safety Monitoring Board  
DUS:  Duplex Ultrasound  
eCRF:  Electronic Case Report Form  
EVAR:  Endovascular Aneurysm Repair  
FIH: First-in-Human  
GMP:  Good Manufacturing Practice  
HIPAA:  Health Care Portability and Accountability Act  
ICF:   Informed Consent Form  
ICH: International Conference on Harmonization  
IFU: Instructions for Use  
IRB: Institutional Review Board  
LVEF  Left Ventricular Ejection Fraction  
MI: Myocardial Infarction  
PC: Percutaneous  
PG:  Performance Goal  
SAE:  Serious Adverse Event  
SC :  Surgical Cut -down  
SDV : Source Document Verification  
STEMI  : ST Elevated Myocardial Infarction  
TAVR:  Transcatheter Aortic Valve Replacement  
TEVAR:  Thoracic Endovascular Aneurysm Repair  
TTH:  Time to Hemostasis  
UADE:  Unanticipated Adverse Device Effect  
VCD:  Vascular Closure Device  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 19 of 73 
 1 Background  
Cardiovascular disease (CVD) is the number one cause of death in the United States 
and worldwide. In 2012 an estimated 17.5 million people worldwide died from CVD  and 
by 2030 more than 23 million people will die annually.1 The older population is growing 
faster than the total population in almost all regions of the world and the difference in 
growth rates is increasing. According to the US Census Bureau there will be 71 million 
people above the age of 65 years, and 19.5 million above the age of 80 in 2030.2 People 
age 85 and over are now the fastest growing portion of many national populations.3 As 
the aging population  continues to rise, there is a corresponding inc rease in the number 
of percutaneous radiologic and endovascular procedures to address CVD. As a result, 
there are continued efforts to improve patient outcomes while reducing procedural 
related complications and health care utilization.  As procedure complexity rapidly 
increases, often involving multiple access points needed for advanced disease 
treatment, efforts to improve outcomes and reduce complications are increasingly 
focused on improvements of vascular access closure.  
 
One area of per cutaneous vascular interventions that has received considerable focus in 
the past decade relates to technologies to achieve rapid and effective control of femoral 
arterial access. Traditionally, cardiac and peripheral interventions have involved 5 ‚Äì8Fr 
shea ths with hemostasis achieved with manual compression at the vascular access 
site.4 Manual compression is associated with extended bed rest/hospital stay and patient 
discomfort. Arteriotomy closure devices were introduced in 1995 as adjuncts or 
alternatives  to manual compression in an attempt to reduce vascular complications, 
reduce time to hemostasis and ambulation and improve patient comfort.5 Currently, a 
number of vascular closure devices (VCD) exist for closure of small femoral arterial 
access sites. Th ese devices are categorized by mechanism that include collagen plug 
devices such as Angio -Seal‚Ñ¢ ( Terumo Corporation , Tokyo, JP ); clip -based closure  : 
StarClose SE ¬Æ (Abbott Vascular, Santa Clara, CA,  USA); sealing agents: Mynx ¬Æ 
(AccessClosure, Mountain View , CA, USA); and sutures for placement around the 
femoral artery: Prostar XL¬Æ Percutaneous Vascular Surgical Device and Perclose 
ProGlide ¬Æ Suture -Mediated Closure System (Abbott Vascular, CA, USA).6 These 
closure devices have primary been developed for peri pheral interventions.  
 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 20 of 73 
 1.1 Need For Large Arteriotomy VCD  
An increasing number of interventional procedures require large -sheath technology (> 
12 Fr), including abdominal aortic aneurysm repair,  thoracic aortic aneurysm repair,  
balloon valvuloplasty, percutane ous aortic valve replacement, and a variety of 
percutaneous ventricular -assist devices. These procedures create challenges for 
hemostasis and minimization of vascular complications. The ability to achieve access 
and closure without surgical cut -down has be come an important part of the vascular 
closure device arena.  
 
Aortic stenosis is a disease with a long latency period followed by rapid progression after 
the appearance of symptoms - approximately 50% of untreated patients will die within 
the first 2 year s after symptoms appear.7,8 Surgical replacement of the aortic valve in the 
absence of serious co -morbidities is associated with low operative mortality. However, 
approximately 30% of patients with severe symptomatic aortic stenosis do not undergo 
surgery due to  advanced age, left ventricular dysfunction, and/or presence of multiple 
co-existing conditions.4, 5 For these high -risk patients, a less invasive treatment, such as 
percutaneous aortic balloon valvuloplasty (BAV), introduced in 1985 by Dr. Cribier , is a 
less invasive alternative to surgical aortic valve replacement (SAVR) for severe aortic 
stenosis in high risk patients.9 The procedure , generally carried out from a transfemoral 
artery approach, involves placement of one or more balloons across a sten otic valve 
followed by inflation to increase the aortic val ve area.10 Despite symptomatic benefit, 
early enthusiasm for BAV was tempered due to high restenosis rates and a failure to 
improve survival rates.11, 12 Echocardiographic restenosis rates at 1 yea r were reported 
to be > 80% while mortalities ranged from 25 -45%.9 Over the last decade BAV is 
experiencing a resurgence largely due to improvements in BAV techniques, changing 
patterns and indications for use, and outcome improvements from initial reports .8, 13 
 
The development of the TAVR/TAVI technique in clinical practice has also generated the 
need for VCD capable of accomplishing effective hemostasis after large diameter 
arteriotomies (up to 24Fr, recently down to 14Fr) as vascular access and closure 
remains a challenge.14 Initially, open surgical access was routinely used to introduce 
large sheaths and catheters. Subsequently, percutaneous techniques have  emerged as 
the new standard, resulting in a less invasive, fully percutaneous procedure.15 One o f the 
first reported randomized stud ies to compare the safety and efficacy of percutaneous 
access with surgical  cutdown in transfemoral TAVR demonstrated no difference in the 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 21 of 73 
 primary endpoint of VARC -2 major and minor complications .16 The overall rate of V ARC -
2 major vascular complications in the study was 13%. A recent meta -analysis of studies 
reporting on percutaneous (PC) versus surgical cut -down (SC) access in TAVR resulted 
in the inclusion of 2 ,513 patients in PC and 1 ,767 patients in SC.17 Major and m inor 
vascular complications, as well as bleeding complications, were comparable between 
the two approaches. The need for surgical intervention for vascular complications was 
comparable between PC and SC groups and there was no difference in perioperative a ll-
cause mortality. The authors concluded PC and SC have similar safety profiles and 
outcomes when used appropriately in selected patients.  
 
Minimally invasive approaches for the treatment of other forms of aortic pathology such 
as endovascular aortic repa ir procedures are now also very common. Endovascular 
aneurysm repair (or endovascular aortic repair /EVAR) , is a type of endovascular surgery 
used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm 
(AAA). EVAR, invented in the early  1990‚Äôs, involves placing a stent graft into the 
aneurysm. Over the years the procedure has been refined to include new generation 
stent -graft and delivery systems. Studies have shown that patients treated with EVAR or 
traditional open surgery demonstrated  fewer early complications with the minimally 
invasive approach and some studies have also observed a lower mortality rate with 
EVAR.18, 19 
 
When used to treat thoracic aortic disease, the procedure is termed thoracic 
endovascular aortic/aneurysm repair (T EVAR). Originally developed by Dake in 1984 
using the same p rinciples as EVAR20, TEVAR  also involves the percutaneous placement 
of an expandable stent graft within the aorta.  
 
1.2 Current Large Arteriotomy VCDs  
Although BAV, TAVR/TAVI, EVAR, and TEVAR are less invasive alternatives to  
conventional surgical approaches, large sized delivery sheaths are still required.  
Management of the arterial access sites often represent a challenge and usually 
requires prolonged manual compression or alternatively suture -mediated closure 
techniques, two of which are commercially available. The Pro star XL was originally 
approved in the US and EU for closure of 5 ‚Äì8Fr access sites and has since gained a CE 
mark for up to 24Fr. The Perclose Pro Glide¬Æ was originally approved for 5 -8Fr and now 
is approved for up to 21Fr. The ProStar¬Æ XL, which provides f our suture needles but, as 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 22 of 73 
 some have suggested, has a somewhat challenging platform, or two ProGlides placed at 
a 40¬∫ angle are placed at the beginning of the procedure leaving knots untied. The 
puncture site is then dilated to the appropriate size and the  sutures are tied once the 
endovascular procedure is complete. For sheath sizes greater than 8Fr, at least two 
devices are required. More recently, a technique has been described using three 
ProGlides; this presumably grabs more segments of the arterial wa ll and provides 
redundancy in case one of the closures fails.21 In the ProGlide¬Æ US FDA approval study, 
the majority of cases used two (74%) or three (18%) devices and some  
used four (4%) and five (2%) closure devices in the procedure.22 
 
1.2.1  Clinical Experien ce With Suture -Based VCDs  
Extensive published clinical experience with the suture based ProGlide and Prostar XL 
for percutaneous closure of large arterial access sites demonstrate relatively high rate of 
technical success and low access -related complication rates with ranges of 81 -100% 
and 6 -19% respectively.15, 23 -34 This data suggests that there is the possibility that use of 
the device in large arterial access sites could result in clinically meaningful savings in 
procedural tim e, patient recovery time and patient length of stay, which may lead to 
improved safety outcomes and reduced  resource use as compared to surgical cut -
down.2, 19  
 
1.2.2  Advantages of Suture -based VCDs  
Several advantages of suture -based closure devices have been su ggested. An analysis 
of a database of 23,813 consecutive interventional coronary procedures that used either 
a collagen plug -based, nitinol clip -based or suture -based VCD, found that suture -based 
VCDs demonstrated a lower risk of vascular complications whe n compared with other 
VCDs irrespective of the success of VCD deployment. Although the collagen plug -based 
VCDs showed lowest failure rate (2.1%), when deployment was unsuccessful, it was 
associated with the highest vascular complication rate as compared t o unsuccessful 
deployment of suture -based or nitinol clip -based VCDs. Deployment failure of suture 
based  VCDs did not impact the vascular complication rate as compared with its  
successful deployment. It was proposed by the author that it was due, in part, to the 
availability of a ‚Äúbailout‚Äù mechanism in the event of deployment failure that permits 
control of the arteriotomy site with sheath replacement or a second attempt at closure 
with VCDs. No bailout mechanism is readily available for the collagen plug -based or the 
nitinol clip -based VCDs.  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 23 of 73 
  
Others have suggested percutaneous closure devices such as the Prostar XL might 
have advantages over surgical cut -down. The smaller scar reaction at the level of the 
groin increases the potential for repeat puncture of  the femoral artery, allowing further 
vascular access when necessary.2 Additionally, the complications associated with use of 
the Prostar¬Æ XL device, while similar in frequency to the rate of complications associated 
with surgical cut -down, can differ mark edly in their seriousness and ease of resolution.2 
 
1.3 Cross -SealTM System  and Indications For Use  
The Cross -SealTM System is indicated for the percutaneous delivery of sutures for 
closing the common femoral artery access site of patients who have undergone 
interventional catheterization procedures using 8F r to 18F r sheaths.  The Cross -SealTM 
System includes the Cross -SealTM Device and three accessories ( Cross -SealTM Knot 
Tyer, Cross -SealTM Knot Pusher, and Cross -SealTM Suture Trimmer). The concept is 
similar to the suture -based VCDs described above but is designed to reduce the 
possible number of devices needed to close  the arteriotomy and to reduce the steps 
required. One device deploys two (2) sutures in three (3) steps. Therefore, in addition to 
the aforementioned potential advantages of suture -based VCDs, other potential 
advantages of the Cross -SealTM System include reduction in number of devices required 
and ease of use . 
 
1.4 Description of Device  
The Cross -SealTM Suture Mediated Vascular Closure Device System ( Cross -SealTM 
System) includes the Cross -SealTM Device and three accessories ( Cross -SealTM Knot 
Tyer, Cross -SealTM Knot Pusher, and Cross -SealTM Suture Trimmer). The Cross -SealTM 
Device ( Figure 1 ) is composed of a Catheter, Suture Delivery System and Handle.  The 
device tracks over a standard 0.038‚Äù or 0.035‚Äù (minimum length 130  cm) guidewire. A 
HEMOSTASIS VALVE loca ted in the middle of the CATHETER limits blood flow from the 
GUIDEWIRE PORT through the CATHETER with or without the guidewire in place.  The 
Suture Delivery System contains NEEDLES, LOCATOR WINGS, and the NEEDLE 
BARREL that control suture placement around  the arteriotomy. The Handle contains the 
SLIDER, BLEEDING INDICATOR, PLUNGER, RESET 1 BUTTON (SLIDER 
RETRACTOR), and RESET 2 BUTTON  (LOCATOR WINGS RETRACTOR). The 
SLIDER triggers a mechanism that opens the LOCATOR WINGS and creates a 
sandwich configuratio n to stabilize the delivery system within the vessel wall. The 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 24 of 73 
 BLEEDING INDICATOR connects to a lumen that has an intraluminal port positioned at 
the distal end of the Suture Delivery System to allow back bleeding  which ensures the 
Suture Delivery System is positioned properly in the femoral artery. The NEEDLE 
BARREL keeps the Cross -SealTM Device from moving deeper inside the vessel, 
stabilizes the device once the LOCATOR WINGS are open and retrieves the disengaged 
suture -carrying NEEDLES. The PLUNGER trig gers the NEEDLES to deploy the sutures 
and simultaneously closes the LOCATOR WINGS.  
 
 
                             Figure 1: Cross -SealTM Device  
 
The Cross -SealTM System includes the following three accessories:  
 
1) Cross -SealTM Knot Tyer is used to provide pre -tie fisherman‚Äôs knots (also 
named Improve Clinch Knot) in the suture.  
2) Cross -SealTM Knot Pusher is used to advance pre -tied knots percutaneously 
to the top of the arteriotomy and secure the knots.  
3) Cross -SealTM Suture Trimmer is used to cut sutures after knots are 
delivered and secured to the top of the arteriotomy.  
 
The Cross -SealTM Knot Tyer ( Figure 2 ) is used for making a Fisherman‚Äôs knot.  
‚Ä¢ The TOP and SIDE HO OK are used to hook the two ends of suture.  
‚Ä¢ The RING TAB, which is connected to PRELOAD STRING, is pulled to trigger 
the process of making the knot. The non -rail end of suture will be brought into 
a preconfigured PRELOAD STRING on the ROTOR.   
‚Ä¢ The SLIDER i s activated to release the loops and slide down the knot.  
 

Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 25 of 73 
  
Figure 2: Cross -SealTM Knot Tyer  
 
The Cross -SealTM Knot Pusher ( Figure 3 ) is used for delivering the knot to the top of the 
arteriotomy. The SNARE WIRE is used to load the rail suture onto the PUSHER BODY, 
which is then pushed to advance the knot percutaneously to the top of arteriotomy.  
 
 
Figure 3: Cross -SealTM Knot Pusher  
 
The Cross -SealTM Suture Trimmer ( Figure 4 ) is used for trimming the suture ends 
percutaneously. The SLIDER controls the suture HOOK by advancing the HOOK for 
loading the sutures. The TRIGGER controls the cutting mechanism located at distal end 
of the CUTTING BARREL.  
 
  
Figure 4: Cross -SealTM Suture Trimmer  
The Cross -SealTM and Accessories are provided sterile to the user as single -use, 
disposable devices.  

Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 26 of 73 
 Cross -SealTM System Specifications  
Feature  Specification  
Cross -SealTM Device   
Guidewire Compatibility  0.038‚Äù or 0.035‚Äù  
Catheter Diameter  9Fr 
Interventional Device Compatibility  8-18Fr  
Overall Device Length  555 mm 
Catheter Length  232 mm 
Locator Wings Length  17.4 mm 
Needle Barrel Length  66 mm 
Needle Barrel Outer Diameter  7 mm 
Cross -SealTM Knot Tyer  
Overall Device length  162 mm 
Cross -SealTM Knot Pusher  
Overall Device length  143 mm 
Cross -SealTM Suture Trimmer  
Overall Device length  185 mm 
 
 
 
1.5 Summary of Clinical Studies  
 
1.5.1  Clinical Feasibility (FIH) Study  
A First -in-Human clinical study was conducted to assess the initial safety and 
feasibility of the Cross -SealTM System GEN 1 .0 to facilitate hemostasis in patients 
undergoing percutaneous transcatheter interventions involving access through the 
femoral arte ry using an 8 -18Fr introducer sheath. Results are demonstrated as 
shown in Table 1 . A total of ten (10) subjects were enrolled at a single site in 
Asuncion, Paraguay between October 26 and 27, 2015. A total of 10 patients 
completed the study. As shown in Table 1 , the patient population consisted of 6 
(60%) men and 4 (40%) women with a mean age of 66.0 years (range 56.3 to 80.2 
years) and mean BMI of 29.2 kg/m2 (range 24.2 to 36.7). The mean estimated 
diameter of femoral artery lumen at the closure site was 9.0 mm and ranged from 
7.1 to 11.0 mm as measured via duplex ultrasound. Size  14Fr introducers were 
utilized in 2 patients and 18Fr introducers were used in 8 patients. The mean 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 27 of 73 
 Cross -SealTM System procedure time was 4 minutes (range 1 -8) and mean TTH 
was 3 minutes and 5 seconds (range 0 -13:00). Total estimated blood loss 
including the interventional procedure was 97.2 mL (range 50 -150). The mean 
Time-to-Ambulation was 3 hours and 12 minutes (range 1:25 -9:12) and mean 
time-to-hospital -discharge was 18 hours  and 17 minutes (range 14:05 to 22:22). 
Four adverse events occurred in 3 patients; 2 hematomas, 1 vessel spasm, and 1 
post obstructive flow in the femoral artery. None of the adverse events were 
serious or unanticipated. All of the events reported were re lated to the procedure 
and not to the device and were resolved without any further action required. 100% 
of patients met the Cross -SealTM System success defined as closure of the 
arteriotomy without the need for any access site related adjunctive surgical or 
endovascular procedures stemming from hemorrhagic, infectious, or ischemic 
complications. 100% of the patients met the primary and sec ondary safety 
endpoints - none had a major or minor vascular complication directly related to the 
Cross -SealTM System as defined by VARC -2 (Valve Academic Research 
Consortium -2). The results of this feasibility study demonstrated that the Cross -
SealTM System is safe and performed as intended.  
 
Table 1. Summary of First -In-Human Clinical Study of the Cross -SealTM System 
(GEN 1 .0) 
Patient Population  
Gender  6 (60%) men and 4 (40%) women  
Age Mean age = 66.0 years (range 56.3 - 80.2 years)  
BMI Mean BMI = 29.2 (range 24.2 - 36.7)  
Diameter of femoral artery 
lumen  Mean = 9.0 mm (range 7.1 - 11.0 mm)  
Procedure  
Introducer size  14 Fr, n = 2  
18 Fr, n = 8  
Cross -SealTM System 
procedure time  Mean = 4 minutes (range 1 -8 minutes)  
TTH Mean = 3:05 minutes (range 0 - 13:00)  
Total estimated blood loss  Mean = 97.2 mL (range 50 -150 mL)  
Technical Success  100%  
Post -procedure  
Time -to-Ambulation  Mean = 3:12  hours  (range 1:25 -9:12)  
Time -to-Hospital -Discharge  Mean = 18:17 hours (range 14:05 - 22:22)  
Adverse Events  N = 3 patients; 2 hematoma, 1 vessel spasm, 1 
post obstructive flow  
 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 28 of 73 
  
 
1.5.2   CE Study  
The CE study was a prospective, multi -center, and single arm study conducted in 
OUS countries. The primary endpoint of effectiveness was technical success 
defined as closure of the arteriotomy without the need for any access -site-related 
adjunctive surgica l or endovascular procedures. The primary endpoint of safety 
was freedom from major VARC -2 events within 30 days of the procedure. Results 
are demonstrated as shown in Table 2. 
 
A total of twenty -six (26) subjects were enrolled across 5 sites in Australia (1), New 
Zealand ( 3), and Taiwan (1), between May 30, 2017 and January 12, 2018.  Study 
results from the total of 26 patients‚Äô data were monitored and shown in  Table 2 . 
The patie nt population consisted of 20 (77%) men and 6 (23%) women with a 
mean age of 76.5 years (range 33 ‚Äì 91 years) and mean BMI is 25.7 (range 20.7 -
36.7). The mean estimated diameter of femoral artery lumen at the closure site 
was 8.3 mm and ranged from 6 mm to  11 mm as measure by ultrasound or CT 
scan. The introducer sheath utilized in study subjects range d from 8Fr to 18Fr. An 
8Fr introducer sheath was utilized in 1 (3.85%) subject, 9Fr introducer sheath was 
utilized in 1 (3.85%) subject, 10Fr introducer sheat hs were utilized in 3 (11.54%) 
subjects, 12Fr introducer sheaths were utilized in 5 (19.23%) subjects, 14Fr 
introducer sheaths were utilized in 7 (26.92%) subjects, 16Fr introducer sheaths 
were utilized in 3 (11.54%) subjects and 18Fr introducer sheaths we re utilized in 6 
(23.08%) subjects. The mean TTH was 1 minute and 11 seconds (range 00:01 ‚Äì 
11:54). The mean estimated total blood loss including the interventional procedure 
was 158 ml (range 5 ‚Äì 600 ml).  
 
A successful ipsilateral ‚Äúpre -close‚Äù percutaneous  technique, defined as closure 
with the  Cross -SealTM System, was achieved in 100% of the subjects with no major 
ipsilateral access site vascular complication at 30 days follow -up. 
 
Table 2 . Summary of CE Clinical Study of the Cross -SealTM System (GEN 2.0)  
Patient Population  
Gender  20 (77%) men and 6 (23%) women  
Age Mean age = 76.5 years (range 33 - 91 years)  
BMI Mean BMI = 25.7 (range 20.7 - 36.7)  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 29 of 73 
 Diameter of femoral artery 
lumen  Mean = 8.3 mm (range 6.0 - 11.0 mm)  
Procedure  
Introducer size  8 Fr, n = 1  
9 Fr, n = 1  
10 Fr, n = 3 
12 Fr, n = 5 14 Fr, n = 7  
16 Fr, n = 3  
18 Fr, n = 6  
TTH Mean = 1:11 minutes (range 00:01 - 11:54)  
Total estimated blood loss  Mean = 158 mL (range 5 -600 mL)  
Technical Success*  100%  
Post -procedure  
Adverse events  N = 12 subjects ( 35 adverse events)  
1 Device related  
1 Device probably related  
33 Non -Device related  
 
* In one case , user exceeded  90 degree s over guidewire and damaged the catheter, successful 
closure was achieved using a second device.  
 
There were 35 adverse events which occurred in 12 subjects. Among the events, 
one is device related, one is probably device related, and 33 are non -device 
related. All adverse events related to access sites complications are in freedom 
from major VARC -2 events within 30 days of the procedure.  
 
One (1) ‚Äúdevice related ‚Äù adverse event occurred as the operators passed the 
device between the catheter  too quickly  at > 90 degree s that led to pre -damage  of 
the guidewire catheter  port. The device was then withdrawn from the tortuous 
vessel resulting  in catheter breakage. The broken portion was successfully 
removed and access site closure was achieved using a second Cross -SealTM 
device. The IFU and training materials were updated accordingly to reinforce the 
importance of passing the device coaxially with an angle less than 60 degree s to 
prevent catheter bending or cracking. Additional on -site training s were provided to 
the operators with agreement that under normal use condition s, catheter breakage 
should not  occur . After training, no catheter bending  or kinking was observed in the 
following 21 cases.  
 
One ‚Äúprobably device related ‚Äù adverse event,  a small ps eudoaneuysm, was 
observed. Such event s are expected potential adverse events from suture -
mediated vascular closure device.  
 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 30 of 73 
 Other adverse events r elated to access sites complications also were observed. 
They were  non-occlusive thrombus and false aneurysm which are expected 
potential adverse events from suture -mediated vascular closure device s. 
An independent Medical Monitor was appointed to review a nd adjudicate all SAEs  
that occurred during the course of the study.  The results of this CE study 
demonstrated that the Cross -SealTM System is safe and performed as intended.  
 
In summary, the 10 subjects enrolled in FIH study and 26 subjects enrolled in CE  
study demonstrated a safety and effectiveness  profile  of Cross -SealTM system. The 
patient population in the study underwent  a variety of procedures including 19 
BAV, 10 TAVI, and 7 TEVAR. The mean of TTH for total 36 subjects (FIH study 
and CE study) is 1 min 10 seconds. The mean TTH observed  by sheath size are 
provided  in Table 3.  
 
Table 3. TTH vs Sheath Size in FIH Study and CE Study  
 Cross -SealTM System GEN 
1.0, FIH Study  Cross -SealTM System GEN 
2.0, CE Study  
Sheath Size  Closure 
Number  Mean  TTH 
(min)  Closure 
Number  Mean  TTH 
(min)  
8Fr N/A N/A N=1 0.23 
9Fr N/A N/A N=1 0.63 
10Fr  N/A N/A N=3 0.47 
12Fr  N/A N/A N=5 0.55 
14Fr  N=2 2.5 N=7 2.26 
16Fr  N/A N/A N=3 1.95 
18Fr  N=8 3.23 N=6 0.7 
 Total (10)  3.08 Total (26)  1.19 
 
 
2 Study Design,  Sample Size  and Duration  
 
2.1 Study Design  
This is a prospective, multi -center, single arm, clinical study  to investigate the safety and 
efficacy of the Cross -SealTM System.  
 
The target population is comprised of subjects scheduled for elective percutaneous 
intervention with introducer sheath  sizes of 8 -18Fr and planned percutaneous 
arteriotomy closure. Applicable procedures include Transcatheter Aortic Valve 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 31 of 73 
 Replacement (TAVR) , Endovascular Aneurysm Repair (EVAR) . Thoracic Endovascular 
Aneurysm Repair  (TEVAR)  and Balloon Aortic Valvuloplasty (BAV) . 
 
2.2 Sample Size  
A minimum of 3 sites and up to 25 sites in the US are expected to participate in the 
study with approximately 100 pivotal subjects enrolled. No more than 15% of the pivotal 
subjects may be enrolled at a single investigational site.  
 
The first 1 -2 subjects  enrolled by each investigator will be considered roll -in subjects to 
allow for physician experience with the inves tigational device. A maximum of 3 study 
investigators and 6 roll -in subjects will be permitted at each investigational site.  
 
In total, up t o 250 subjects will receive the investigational device as part of the clinical 
study.  
 
2.3 Study Duration  
Study enrollment is expected to occur over a 10 to 12 month  period . Imaging and follow -
up procedures will continue through 30 days post -procedure. Subject s with an abnormal 
DUS  at 30 days will have a repeat DUS at 60 days post -procedure (all DUS will be 
analyzed by an independent core laboratory). The total study duration is expected to be 
approximately 24 months . 
 
Note: Due to the COVID -19 pandemic, some patient follow -up visits have been delayed 
greater than 6 months or completely missed; therefore, making data collection extremely 
difficult (e.g., missed DUS assessments) to support some of the secondary endpoints. 
To evaluate safety, we ha ve added an unscheduled visit and telephone assessment (if 
needed) to be conducted as soon as possible based on physician and hospital 
regulatory discretion.  
 
3 Study Objective, Hypothesis, and Endpoints  
 
3.1 Study Objective  
The study objective is to demonstrate  the safety and efficacy of the investigational 
device to achieve hemostasis of common femoral artery access site in subjects 
undergoing percutaneous endovascular procedures utilizing 8 -18Fr introducer sheath . 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 32 of 73 
 3.2 Study Hypothesis  
Safety:  
The freedom from major complications at the target limb access site within 30 days post -
procedure will be greater  than the specified  PG. 
 
Efficacy:  
Following use of the investigational device , the mean TTH  will be less than the specified 
PG. 
 
3.3 Endpoints  
This clinical study will evaluate the primary and secondary endpoints described below.  
 
3.3.1  Primary E ndpoint s   
Primary Safety Endpoint:  
‚Ä¢ Freedom from major complications of the target limb access site within 30 days 
post-procedure which includes the following:  
 
Major Complications:  
‚Ä¢ Vascular injury attributable to the investigational device that requires surgical 
repair, stent -graft, or balloon angioplasty  
‚Ä¢ Access site -related bleeding attributable to the investigational device that 
requires transfusion  
‚Ä¢ Any new access site -related ips ilateral lower extremity ischemia attributable to 
the investigational device and documented by patient symptoms, physical exam, 
and/or decreased or absent blood flow on lower extremity angiogram  
‚Ä¢ Surgery for access site -related nerve injury attributable to the investigational 
device  
‚Ä¢ Permanent (lasting > 30 days) access site -related nerve injury attributable to the 
investigational device  
‚Ä¢ Access site infection requiring intravenous antibiotics and/or extended 
hospitalization  
 
 
 
 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 33 of 73 
 Primary Efficacy Endpoint:  
‚Ä¢ The mean TTH in the Common Femoral Artery (CFA) of the target limb access 
site with use of the investigational device.  
 
TTH will be evaluated from time of procedural sheath removal to first 
observed cessation of CFA bleeding (excluding cutaneous or 
subcutaneous oozing  at access site ) in the target limb for subjects not 
requiring adjunctive intervention.  
 
If a sheathless sy stem is used during the procedure, TTH will be  
calculated  from final introducer sheath removal to first observed cessation 
of CFA bleeding (excluding cutaneous or subcutaneous oozing  at access 
site) in the target limb  for subjects not requiring adjunctive intervention.  
 
Adjunctive Intervention is defined as any use of surgical or endovascular 
intervention OR firm/occlusive manual pressure needed to achieve 
access site hemostasis (light/non -occlusive pressure to control cutaneous 
or subcutaneous oozing at the access site is excluded).  
 
3.3.2  Secondary Endpoints  
Secondary Safety Endpoints:  
‚Ä¢ The freedom from minor  complications at the target limb access site within 30 
days post -procedure which includes the following:  
 
Minor Complications :  
o Non-treated pseudoaneurysm attributable to the investigational device 
and documented by DUS  
o Pseudoaneurysm attributable to the investigational device and treated 
with ultrasound -guided compression, ultrasound -guided thrombin 
injection. or ultrasound -guided fibrin adhesive injection  
o Non-treated or treated arteriovenous (AV) fistula attributable to  the 
investigational device and documented by DUS  
o Access site hematoma greater than or equal to 10 cm in diameter, 
attributable to the investigational device, and confirmed by DUS  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 34 of 73 
 o Late (following hospital discharge) access site -related bleeding in target 
limb 
o Lower extremity arterial emboli attributable to the investigational device  
o Vein thrombosis attributable to the investigational device  
o Transient access site -related nerve injury attributable to the 
investigational device  
o Access site wound dehiscence  
o Access site infection treated with intramuscular or oral antibiotics  
‚Ä¢ Device Related Complications (DRCs) and procedural complications within 30 
days post -procedure  
‚Ä¢ Evaluation of all Adverse Events (AEs) from time of investigational device 
use within 30 days post -procedure, and through 60 days post -procedure 
for subject‚Äôs requiring a repeat DUS, including major and minor 
complications  
 
Secondary Efficacy E ndpoints:  
‚Ä¢ Technical Success:  defined as achievement of hemostasis with the 
investigational device without the need for any access -site-related adjunctive 
surgical or endovascular intervention  (target limb only) .  
‚Ä¢ Access site closure success:  defined as technical success  and freedom from 
major complications within 48 hours of the index procedure or hospital discharge, 
whichever occurs first  (target limb only) . 
‚Ä¢ Treatment Success:  defined as technical success  and freedom from major 
complications  through 30 days follow -up. 
‚Ä¢ Subjects requiring adjunctive surgical or endovascular intervention  to achieve 
hemostasis of the access site (target limb only) including type of adjunctive 
intervention.  
‚Ä¢ Subjects receiving adjunctive manual compression following use of the 
investigational device to achieve hemostasis of the access site (target limb only) . 
o Type of compression applied (light or firm, where light compression is 
defined as non -occlusive (i.e., ‚Äúpatent hemostasis‚Äù) allowing distal blood 
flow, and firm compression defined as occlusive prohibiting distal blood 
flow.  
‚Ä¢ Time -to-Ambulation:  defined  as elapsed time from final procedural sheath 
removal to time when the subject stands and walks at least 20 feet without 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 35 of 73 
 re-bleeding.  
‚Ä¢ Time -to-Discharge (i.e., time of actual discharge defined as the elapsed time 
between final procedural sheath removal and when the subject is actually 
discharged from the hospital)  
‚Ä¢ Occurrence of device failure  as defined in Section 13.0  
 
3.3.3  Exploratory Endpoints  
‚Ä¢ Time -to-Device -Deployment defined as time of guidewire removal during device 
insertion to time of guidewire reinsertion during device removal, and overall 
procedure time defined as time of first skin nick/incision to achievement of 
hemostasis in the access site (target limb only)  
‚Ä¢ Time -to-Dischargeability (i.e., discharge eligibility defined as the elapsed time 
between final procedural sheath removal and time when the subject is medically 
able to be discharged based solely on the assessment of the access site as 
determined by the investigator.  
 
4 Study Design  
This is a prospective, multi -center, single arm, clinical  study  to investigate the safety and 
efficacy of the Cross -SealTM System. The safety and efficacy will be evaluated 
immediately post -procedure , prior to hospital discharge , through 30 days post -
procedure,  and through 60 days  post-procedure  for subjects req uiring a repeat DUS .  
 
Study sites will make every attempt to conduct a telephone assessment for patients 
whose follow -up visits have been affected COVID -19. The assessment will evaluate 
AEs, concomitant medications and groin health status (which would oth erwise be 
evaluated by a physical exam and DUS).  
 
A subject is considered enrolled  into the study if the subject has signed the ICF and 
meets all eligibility criteria.  
 
4.1 Eligibility Criteria  
Inclusion Criteria  
1. Subjec t is ‚â• 18 years old  
2. Subject is scheduled for elective or planned (i.e., not emergent or urgent ) 
percutaneous transcatheter interventional procedures involving access through 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 36 of 73 
 the femoral artery using 8 -18 Fr introducer sheaths (i.e. BAV, TAVR/TAVI, 
EVAR, TEVAR)  
3. Subject  is ab le to undergo emergent vascular surgery if a complication related to 
the vascular closure necessitates such surgery  
4. Subject  is willing and able to complete follow -up requirements  
5. Subject  has the mental capacity to consent for themselves (i.e. , does not req uire 
the use of a Legally Authorized Representative),  and signs a written Informed 
Consent Form (ICF)  prior participating in the study  
 
Subject s will not be permitted to participate in the study if they meet any of the following 
general exclusion criteria and/or intra -procedure exclusion criteria:  
 
General Exclusion Criteria  
1. Prior intra -aortic balloon pump at access site  
2. Subject s with severe inflow disease ( iliac artery diameter stenosis > 50%)  and/or 
severe peripheral arterial disease (Rutherford Classification 5 or 6), as confirmed 
with prior standard of care CT Imaging, duplex ultrasound, and/or intra -
procedural fluoroscopy  
3. Common femoral artery lumen diameter is < 5 mm  
4. In opinion of the investigator, significant scarring of the target access si te which 
would preclude use of the device in accordance with the IFU  
5. Prior target artery closure with any closure device < 90 days, or closure with 
manual compression ‚â§ 30 days prior to index procedure  
6. Prior vascular surgery, vascular graft, or stent in re gion of access site  
7. Subject s receiving glycoprotein IIb/IIIa inhibitors before, during, or after the 
catheterization procedure  
8. Subject s with significant anemia (Hgb < 10 g/dL, Hct < 30%)  
9. Subject  with known bleeding disorder including thrombocytopenia (pla telet count 
< 100,000), thrombasthenia, hemophilia or Von Willebrand‚Äôs disease  
10. Subject  with renal insufficiency (serum creatinine level > 221¬µmol/L or 2.5 
mg/dL) , on dialysis therapy,  or with renal transplant  
11. Known severe allergy to contrast reagent that cannot be managed with 
premedication  
12. Inability to tolerate aspirin and/or other anticoagulation /antiplatelet  treatment  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 37 of 73 
 13. Planned anticoagulation therapy post -procedure such that ACT is expected to be 
elevated above 350 seconds for more than 24 hours after th e procedure  
14. Connective tissue disease (e.g., Marfan's Syndrome)  
15. Thrombolytics (e.g. t -PA, streptokinase, urokinase), Angiomax (bivalirudin) or 
other thrombin -specific anticoagulants ‚â§ 24 hours prior to the procedure  
16. Recent (within 8 weeks) cerebrovascular accident or Q -wave myocardial 
infarction  
17. Subject s who are morbidly obese (BMI > 40 kg/m2) 
18. Planned major intervention or surgery , including planned endovascular 
procedure in the target leg,  within 30 days following the interventional procedure  
19. Subject  unable to ambulate at baseline  (i.e., confined to wheelchair or bed)  
20. Currently participating in a clinical study of an investigational device or drug that 
has not completed its primary study e ndpoint  
21. Known allergy to any device component  
22. Subject  is known or suspected to be pregnant or lactating  
23. Evidence of active systemic or local groin infection  
24. Subject  has other medical, social or psychological problem that in the opinion of 
the investigator  precludes them from participating  
25. Subject  is mentally incompetent or a prisoner  
26. New York Heart Association (NYHA) Class IV heart failure that is uncontrolled 
and requires treatment in the Intensive Care Unit within 24 hours prior to the 
index procedure  
27. Left Ventricular Ejection F raction  (LVEF)  < 20%  
28. Unilateral or bilateral lower extremity amputation  
29. Known existing nerve damage in the target leg  
30. Subjects who have already participated in this IDE study  
 
Intra-Procedure Exclusion Criteria  
31. Access site above the most inferior border of the inferior epigastric artery (IEA) 
and/or above the inguinal ligament based upon bony landmarks  
32. Access site in the profunda femoris or superficial femoral arteries, or the 
bifurcation of these vessels  
33. Ipsilateral femoral  venous sheath during the catheterization procedure  
34. Common femoral artery calcium  at the arteriotomy site (i.e., target access site) , 
which is visible with prior CT Imaging and/or duplex ultrasound  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 38 of 73 
 35. Subject  in which  there is difficulty inserting the introdu cer sheath or need for 
greater than 2 ipsilateral arterial punctures at the start of the catheterization 
procedure  
36. Difficulty in obtaining vascular access resulting in multiple arterial punctures 
and/or posterior arterial puncture  
37. Evidence of a pre-existing hematoma  (> 1.5 cm in diameter) , arteriovenous 
fistula, pseudoaneurysm , or intraluminal thrombosis  at the access site  
38. Marked tortuosity (at the investigator‚Äôs discretion) of the femoral or external iliac 
artery in the target leg based on prior  CT imaging, fluoroscopy, and/or duplex 
ultrasound  
39. Angiographic evidence of arterial laceration, dissection, or stenosis in the femoral 
artery that would preclude use of the investigational device  
40. Target arteriotomy >18F sheath  
 
The inclusion of subjects  using other medications will be left to the discretion of the 
treating investigator. All such medication use, dose, and schedule will be recorded and 
documented.  
 
4.2 Subject Enrollment  
A minimum of 3 sites and up to 25 sites in the US are expected to participa te in the 
study with approximately 100 pivotal subjects enrolled. No more than 15% of the pivotal 
subjects may be enrolled at a single investigational site. 
 
The first 1 -2 subjects enrolled by each investigator will be considered roll -in subjects to 
allow for physician experience with the investigational device. A maximum of 3 study 
investigators and 6 roll -in subjects will be permitted at each investiga tional site.  
 
In total, up to 250 subjects will receive the investigational device as part of the clinical 
study.  
 
5 Ethics  
 
5.1 Role of the Sponsor  
The Sponsor  has the overall responsibility for the conduct of the study, including 
assurance that the study meets  all regulatory requirements. In this study, the Sponsor 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 39 of 73 
 will have certain direct responsibilities  and will delegate other responsibilities to the 
Clinical Research Organization (CRO). The Sponsor will conduct all its responsibilities in 
compliance with the Code of Federal Regulations (CFR).  
 
5.2 Role of Clinical Research Organization  
The Clinical Research Organization s (CRO s) will support the data management and 
safety oversight throughout study conduct which includes, but is not limited to, safety 
review boards (DSMB, CEC), informing the Sponsor of any unanticipated adverse 
device effects  (UADEs), serious adverse events (SAEs), and deviations from the 
protocol as appropriate. The CRO will conduct all its responsibilities in compliance with 
the Code of Federal Regulations (CFR).  
 
5.3 Ethics Review  
The final study protocol  and written Informed Consent Form must be approved in writing 
by an Institutional Review Board (IRB). The principal investigator is responsible for 
informing the IRB of any amendments to the protocol in accordance with local 
requirements. In addition, the IRB must approve all advertising used to recruit subjects 
to the study. The protocol must be re -approved by the IRB annually, as local regulations 
require.   
Progress reports and notification of serious, unexpected adverse events will be provided 
to the IRB according to local regulations and guidelines.  
5.4 Ethical Conduct of the Study  
The study will be performed in accordance with ethical principles that have their origin in 
the Declaration of Helsinki and are consistent with the ICH/Good Clinical Practice, and 
applicable regulato ry requirements.  
 
5.5 Written Informed Consent  
Written Informed Consent must be obtained prior to any study -related procedures *. The 
principal investigator will ensure that proper informed consent is provided, including 
ensuring the subject is given full and adequate oral and written information about the 
nature, purpose, possible risks and benefits of the study. Subjects must also  be notified 
that they are free to discontinue/withdraw from the study at any time. The subject must 
be given the opportunity to ask questions and allowed time to consider the information 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 40 of 73 
 provided. The principal investigator will ensure that the subject ha s met all eligibility 
criteria prior to enrollment in the study.  
 
The principal investigator must store the original, signed written ICF.  A copy of the 
written ICF must be given to the subject. Any m odifications made to the ICF must be 
approved by the IRB , Sponsor, and FDA if applicable.   
 
*Pre-procedure assessments considered standard of care completed prior to obtaining 
informed consent do not need to be repeated if performed within 30 days of the 
procedure unless the investigator feels it is medically necessary, or unless otherwise 
specified (e.g., pregnancy test).  
 
5.6 Subject Data Protection  
In accordance with the Health Information Portability and Accountability Act (HIPA A), the 
written Informed Consent Form must include a subject authorization to releas e medical  
information to the study Sponsor and or allow the Sponsor or their designate, a 
regulatory authority, or IRB access to subject‚Äôs medical information that includes all 
hospital records relevant to the study, including subjects‚Äô medical history.  
 
5.7 Subject Withdrawal  
A subject‚Äôs participation in the study is voluntary. Subjects may withdraw their consent 
from participation in the study at any time. A subject may withdraw completely or may 
withdraw but leave the authorization to access their medical r ecords in effect.  The 
investigator will take every reasonable measure to follow the subject  for vital status and 
clinical events. Should a subject exit the study for any reason, the investigator will 
document the reason for study exit, if known, and record  in the study database.   
 
5.8 Discontinuing Subject Participation  
A subject‚Äôs continued participation in the study may be terminated for the following 
reasons:  
 
 1. Serious or severe adverse event or unanticipated adverse device effect.  
 2. Termination of study by the Sponsor.  
 3. Investigator determines that continued participation is not in the best interest of 
the subject.  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 41 of 73 
  4. Subject withdrawal of consent at any time.  
 
6 Device Supply Information  
 
6.1 Shipping  
An initial  supply of the investigational device  will be shippe d to investigational site when 
the site is approved  by the Sponsor after all requirements, such as IRB approval and 
conduct of a Site Initiation Visit, are completed . Resupply of investigational devices 
during the study will be facilitated by  the Sponsor, and/or designate .  
 
6.2 Labeling  
Labelling  of investigational devices  will be performed in accordance with the Good 
Manufacturing Practices (GMP) for Medical Devices of the Quality System Regulations 
(QSR). The devices will be package d in individual t rays with a peel -pack design. Each 
individual device tray will be packaged in a  pouch within a  cardboard box and will be 
labeled with the statement:  ‚ÄúC AUTION  Investigational Device. Limited by Federal Law 
to Investigational Use‚Äù. Information on the  investigational device  label will indicate the 
identity, quantity , and storage conditions.  
 
6.3 Storage  
All investigational device s must be kept in a secure place under appropriate storage 
conditions. A description of the appropriate storage and shipment conditions will be 
specified on the device label and/or in the IFU. The stored device supplies must be 
accessible to authorized sta ff only, who must have adequate control of storage area 
temperature in order to maintain stability of the device supplies as specified in the IFU. 
The investigational devices should be stored in the original pack including tray, pouch, 
and box, until use. For further information, investigators should refer to the 
investigational device label and/or IFU.  
 
6.4 Accountability  
The investigator and delegated  study personnel are responsible for maintaining a ccurate 
dispensing records of the investigational device. All devices must be accounted for, 
including devices accidentally or deliberately destroyed. All records for number of 
devices received, dispensed, and returned must be documented. Under no 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 42 of 73 
 circumst ances will the investigator allow the investigational device to be used other than 
as directed by the protocol without prior Sponsor approval.  
 
6.5 Return of a Malfunctioning/ Failed Device  
In the case where a device has  malfunctioned and/or failed, the i nvestigator must make 
every possible effort to return the device to the S ponsor, unless there is a known 
contamination with an infectious disease (i.e. Hepatitis B, C or HIV). Upon completion of 
the appropriate electronic  Case Report Form (eCRF)  for failed device, the S ponsor will 
contact the site with complete return instructions.   
 
7 General Procedures  
 
7.1 Baseline/Pre -Procedure Visit  
Prior to the procedure, subjects must sign the informed consent form, meet all of the 
inclusion and none of the exclusion criteria and complete the following assessments:  
 
The following baseline evaluations are required within 30 days prior to  the Index 
Procedure unless otherwise specified:  
‚Ä¢ Informed Consent Form  
‚Ä¢ Eligibility Criteria  
‚Ä¢ Blood Tests including Complete Blood Count (CBC), Platelet Count, Serum 
Creatinine, Hemoglobin (HGB), Blood Urea Nitrogen (BUN), and Hematocrit 
(HCT) to assess eligibility crit eria (collected within 2 weeks prior to index 
procedure)  
‚Ä¢ Medical History/Demographics  
‚Ä¢ Pregnancy test if female of child -bearing potential (within 7 days prior to  
procedure  according to site standard of care ) 
‚Ä¢ Target limb  standard of care  CT Imaging to docum ent eligibility  criteria 
requirements for CFA diameter and stenosis (performed up to 6 months prior to 
index procedure)  
‚Ä¢ Concomitant Medications (Anticoagulation / Antiplatelets Only)  
 
Note:  For subject s that do not have a standard of care  CT Imaging modality, a micro 
puncture and angiogram intra -procedure, may be utilized to confirm eligibility criteria.  
 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 43 of 73 
 7.2 Index Procedure  
Subjects that meet the general eligibility criteria and have signed the informed consent 
will have their scheduled interventional procedure (i.e., index procedure) performed in 
accordance with investigator/investigational site standard practices. Subjects on warfarin 
or anti -Xa inhibitors must be managed per institutional pre -interventional procedure 
standard of care.  
 
Prior to the use of the investigational device, the investigator will assess the subject for 
the intra -procedure eligibility criteria to confirm enrollment in the study. If the subject is 
enrolled (i.e., signed informed consent and meets all eligibility c riteria, including intra -
procedural), the investigational device will be utilized for femoral artery closure according 
to the IFU.  Enrolled subjects must also receive anticoagulant and/or antiplatelet 
medication during the index procedure in accordance wit h the IFU.  
 
If the subject does not meet all eligibility criteria, the subject cannot be enrolled. The 
subject will be considered a screen ing failure and will not have the investigational device 
utilized. The investigator will perform the femoral artery cl osure according to their 
standard practice and the subject will not be followed as part of the study protocol. After 
completion of the interventional procedure, subjects will be treated in accordance with 
hospital standard of care and the study protocol.   
 
Note:  Only one single access site per subject will be eligible for use of the 
investigational device  and any additional access sites will be managed according to the 
operator‚Äôs standard of care. It is recommended the investigational device be used on th e 
primary access site (i.e., ipsilateral) as on the side with the intended larger procedural 
sheath size.  Should the procedure require a sheath that exceeds 18Fr  at the primary 
access site  (i.e., does not meet the eligibility criteria), the subject may st ill be enrolled if 
the secondary access site (i.e., contralateral to the primary access site) is within the 
acceptable range of 8 -18Fr and meets the eligibility criteria.  
 
At the end of the index procedure  and p rior to closure of the arteriotomy with the 
investigational device , the Activated Clotting Time (ACT ) for heparinized subjects will be 
determined. It is required that the ACT < 350 seconds immediately prior to sheath 
removal to minimize the risk of bleeding; the investigator may use their standard o f care 
and/or medication to control the ACT.  In addition, if uncontrolled hypertension (systolic 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 44 of 73 
 blood press > 180 mm Hg or diastolic blood pressure > 110 mm Hg) or hypotension 
(Systolic blood pressure < 90 mm Hg) is observed just prior to planned vascula r closure, 
every effort should be made to appropriately manage according to the investigator‚Äôs 
standards of care.  
 
After the vascular closure has been completed, cutaneous or subcuta neous oozing may 
be treated with light (non -occlusive) pressure applied to the access site manually, with a 
dressing, or as per the investigator‚Äôs standard procedure for suture -mediated closure 
devices. Such oozing will not affect the TTH assessment or be consid ered an adverse 
event unless severe enough to require further treatment (i.e. surgery or other 
intervention). TTH, defined as elapsed time from procedural sheath removal to the first 
observed cessation of CFA bleeding (excluding cutaneous or subcutaneous o ozing  at 
access site ), will be recorded.  If a sheathless system is used during the procedure, TTH 
will be calculated from final introducer sheath removal to first observed cessation of CFA 
bleeding (excluding cutaneous or subcutaneous oozing  at access site ) in the target limb.  
 
In the event of  failure to achieve hemostasis  following use of the investigational device 
and based on the investigator‚Äôs assessment  of bleeding , a bail -out method  such as 
manual compression, compression assisted devices , secondary c losure device  and/or a 
surgical repair to obtain hemostasis should be performed according to the investigator‚Äôs 
standard practice and the subject will be followed per the protocol.  Should a secondary 
closure device be utilized for the bail -out method, it must be commercially available and 
cannot be the investigational device.  
 
The following will be conducte d during the index procedure:  
‚Ä¢ Eligibility Criteria (including intra -procedure)  
‚Ä¢ Femoral artery angiography to assess femoral artery and puncture site pri or to 
utilizing the investigational device and after procedure for assessment of major  
and/or minor complications  
‚Ä¢ Activated Clotting Time (ACT)  
‚Ä¢ Time -to-Hemostasis (TTH)  
‚Ä¢ Concomitant Medications (Anticoagulation / Antiplatelets Only)  
‚Ä¢ Adverse Events (observed from time of enrollment)  
 
 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 45 of 73 
  
 
 
 
 
 
 
 
Page Section Intentionally Blan k
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.4 
  
29 JUL 2020                              CONFIDENTIAL   Page 46 of 73 
  
Table 2:  
Schedule of 
Events  Assessment  Screening / 
Baseline  Index 
Procedure  Post Procedure to 
Hospital  
Discharge  30 Day Follow -
up 60 Day Follow -
up‚àû Unscheduled  
Visit ‚ÅÇ         
Informed Consent  X      
Eligibility Criteria  X X     
Medical History/Demographics  X      
Pregnancy Test¬∂  X      
Blood Tests¬µ X      
Femoral Artery Imaging (CT scan) ‚Äì within 6 months prior to 
index procedure¬ß  X      
Femoral Artery Angiography¬±   X     
Activated Clotting Time (ACT)   X     
Time -to-Hemostasis (TTH)‚â†   X     
Time -to-Ambulation‚Ä†    X    
Time -to-Dischargeability‚Ä°    X    
Time -to-Discharge (TTD)¬•    X    
Targeted Physical Exam, including groin exam     X X Xa 
Femoral Duplex Ultrasound (DUS)*     X X Xa 
Concomitant Medications (Anticoagulation / Antiplatelets Only)  X X X X X X 
Adverse Events ‚åò  X X X X X 
Phone Call assessment of AEs and patient condition       X 
¬µ Blood Tests include Complete Blood Count (CBC), Platelet Count, Serum Creatinine, Hemoglobin (HGB), Blood Urea Nitrogen (BUN) , and Hematocrit (HCT) to   
  assess eligibility criteria (collected within 2 weeks prior to index procedure)  
¬∂ Pregnancy test if female of child -bearing potential (collected within 7 days prior to index procedure according to site standard of care)  
* Femoral Duplex Ultrasound is required for assessment of groin/access site related complications. If subject has an abnormal  30 day DUS , subject will be required to return for an additional DUS at 
60 days post -index procedure.  
¬ß Standard of care CT Imaging modality performed to assess femoral artery quality per trial criteria (collected within 6 mont hs prior to index procedure). Note: If subject does not  have a previous CT 
imaging modality, a micro puncture and angiogram intra -procedure may be utilized to confirm eligibility criteria.  
¬± Femoral Angiography for assessment of quality of femoral artery and puncture site prior to utilizing investigational device.  
‚åò Adverse events should be recorded at any time during the course of the study from time of enrollment through 30 days post -index procedure. Should a subject require a repeat DUS, AEs will be 
collected through 60 days post -index procedure.  
‚Ä† Time -to-Ambulation is defined as elapsed time from final procedural sheath removal and time when the subject stands and walks without  re-bleeding.  
‚Ä°Time -to-Dischargeability (i.e., discharge eligibility defined as the elapsed time betw een procedural sheath removal and time when the subject is medically able to be discharged based solely on the 
assessment of the access site as determined by the investigator.  
 ¬•Time -to-Discharge defined as the elapsed time between final procedural sheath removal and when the subject is actually discharged from the hospital  
‚â†TTH will be evaluated from time of procedural sheath removal to first observed cessation of CFA bleeding (excluding cutaneou s or subcutaneous oozing) in the target limb for subjects not  requiring 
adjunctive intervention. If a sheathless system is used during the procedure, TTH will be from final introducer sheath remova l to first observed cessation of CFA.  
‚àû 60 Day Follow -Up Visit assessments are only required if the subject returns to c omplete a repeat DUS following an abnormal 30 Day DUS  
‚ÅÇ Unscheduled  visits can occur at any time. Ensuring the safety of trial participants is paramount. Surveillance for adverse events and con comitant medications can be collected via telephone 
contact or similar if the patient is unable to make an in -person visit.  
a If clinically indicated.  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 47 of 73 7.3 Investigational Device  Set-up and Preparation   
Please refer to the IFU for additional guidance for the investigational device.  
 
7.4 Concomitant Medical Therapy  
Subjects enrolled in this study should be medicated  according to investigator‚Äôs standard of 
care prior to, during, and after the interventional procedure. Enrolled subjects must also 
receive anticoagulat ion and/or antiplatelet medication during the index procedure in 
accordance with the IFU.  
 
Any medications should be recorded on the appropriate eCRF.  
 
7.5 Follow -up Procedures  
Subjects will be evaluated prior to discharge and through 30 days post -procedure. Subjects 
with an abnormal 30 Day DUS will be required to complete a repeat DUS at 60 days post -
procedure. All follow -up visit dates will be calculated based on a 30 day calendar.  
 
7.5.1  Post -Procedure through Hospital Discharge  
The subject may ambulate or be discharged when clinically stable, at the investigator‚Äôs 
discretion.  
 
The following information will be collected  from procedure through hospital discharge : 
‚Ä¢ Time -to-Ambulation , defined as elapsed time from final procedural sheath removal 
to time when the subject stands and walks at least 20 feet without re -bleeding  
‚Ä¢ Time -to-Dischargeability, i.e., discharge eligibility defined as the elapsed time 
between procedural sheath removal  and time when the subject is medically able to 
be discharged based solely on the assessment of the access site as determined 
by the investigator  
‚Ä¢ Time -to-Discharge (i.e., time of actual discharge defined as the elapsed time 
between final procedural sheath removal and when the subject is actually 
discharged from the hospital)  
‚Ä¢ Concomitant Medications (Anticoagulation / Antiplatelets Only)  
‚Ä¢ Adverse Events  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 48 of 73 7.5.2  30 Day Follow -Up (30 ¬± 7 days)  
All subject s will be asked to return to the investigational site 30 days p ost-procedure. This 
visit will conclude the subject ‚Äôs participation in the study unless the subject  has an abnormal 
30 day DUS  in which case the subject will return for a repeat DUS at 60 days post -
procedure.  
 
The following data will be collected:    
‚Ä¢ Femoral Duplex Ultrasound  (DUS)  for assessment of groin/access site related 
complications  (target limb only)  
‚Ä¢ Targeted physical exam, including groin exam  
‚Ä¢ Concomitant Medications (Anticoagulation / Antiplatelets Only ) 
‚Ä¢ Adverse Events  
 
7.5.3  60 Day Follow -Up (60 days ¬± 14 days)  
All subjects  with an abnormal DUS at 30 days post -procedure will be asked to retu rn to the 
investigational site at 6 0 days post -procedure  to complete a repeat DUS.   
 
The following data will be collected:    
‚Ä¢ Repeat DUS for assessment of groin/access site related complications  (target limb 
only)  
‚Ä¢ Targeted physical exam, including groin exam  
‚Ä¢ Concomitant Medications (Anticoagulation / Antiplatelets Only)  
‚Ä¢ Adverse Events  
 
7.5.4  Unscheduled Visit  
 
The unscheduled visit is designed to evaluate the ongoing safety of enrolled patients 
outside the protocol defined 30 -day and/or 60 -day visits.  
 
Patients with missed or incomplete in -person protocol defined visits due to the CO VID-19 
pandemic will not be considered lost -to-follow -up/withdrawn by the Sponsor. Rather, the 
unscheduled visit can be used to reconsent the patient for this extended follow up to 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 49 of 73 evaluate their safety. The Interim follow up visit will be available for up  to 12 months from 
the primary study index procedure and subjects should return as soon as reasonably 
possible unless the patient wishes to be withdrawn from the study.  
 
The following data will be collected  during the unscheduled visit:     
‚Ä¢ DUS for assessment of groin/access site related complications  in target limb only (if 
not completed already or if repeat is needed (e.g., missed 30 -day and/or 60 -day 
visit))  
‚Ä¢ Targeted physical exam, including groin exam (if not completed already or if repeat 
is nee ded (e.g., missed 30 -day and/or 60 -day visit))  
‚Ä¢ Concomitant Medications (Anticoagulation / Antiplatelets Only)  
‚Ä¢ Adverse Events  
 
If the patient will not or cannot return for an unscheduled visit , the study site should 
contact the patient via telep hone to determine AEs and patient condition .  
 
7.6 Clinical Data Collection  
Information about subject demographics, eligibility requirements, procedure summary, 
concomitant mediations as well as any procedure complications and/or adverse events will 
be collected on e CRFs provided by the S ponsor. The eCRFs should accurately reflect data 
contained in the subject‚Äôs  medical  records (i.e. source documents) . 
 
8 Adverse Events  
The reporting and recording of adverse events is crucial to the evaluation of an 
investigational devi ce, and to the development of labeling information that appears in the 
IFU. During a clinical study, the reporting of adverse experience information can lead to 
important design changes in the new device, as well as provide integral safety data. The 
invest igator will monitor each subject for clinical and laboratory evidence of adverse events 
on a routine basis throughout the procedure.  
Subject safety will be monitored via the reporting of adverse events occurring from the time 
of enrollment through study completion. Any pre -existing condition known to the investigator 
will not be reportable as an adverse event unless that condition worse ns during the study.   
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 50 of 73  
Where an adverse event has, by its nature, a prolonged course, the event will be considered 
a single event and not multiple events. For example, if a subject develops end -stage renal 
failure requiring regular dialysis, the event is considered as end stage renal failure, not 
multiple single renal events.   
 
The i nvestigator is not obligat ed to actively seek adverse events from a subject once a 
subject has completed/exited the study.  If the investigator learns of any adverse event  at 
any time after a subject‚Äôs exit  from the study, and there is a reasonable possibility that it is 
related to investigational device, the  investigator should promptly report it to the Sponsor.  
 
8.1 Definitions  
An adverse event (AE) is defined as an unwanted medical occurrence in a subject. This 
definition does not imply that there is a relationship between the AE and the device 
under investigation. This can include, but is not limited to, a change in the subject ‚Äôs 
health status from baseline that is related to the disease process, interventional 
procedures, investigational  device, and/or side effects to medications.   
 
An adverse device effect  is defined as those adverse events that are caused by , or 
related to , the investigational device.  
 
An unanticipated adverse device effect  (UADE) is an adverse device effect that is not 
described in the study risk assessm ent or the informed consent.  ‚ÄúA ny serious adverse 
effect on health or safety or any life -threatening prob lem or death caused by, or 
associated with, a device, if that effect, problem, or death was not previously identified 
in nature, severity, or degree of incidence in the investigational plan or application 
(including a supplementary plan or application), or  any other unanticipated serious 
problem associated with a device that relates to the rights, safety, or welfare of subjects‚Äù 
(21 CFR 812.3(s)).  
A serious adverse event  (SAE) is an adverse event that led to a death or led to a 
serious deterioration in the health of a subject that:  
1. Resulted in a life -threatening illness or injury,  
2. Resulted in a permanent impairment of a body structure or body function,  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 51 of 73 3. Required in -subject hospitalization or prolongation of existing 
hospitalization,  
4. Resulted in medical or surgical intervention to prevent impairment to body 
structure or a body function, or  
5. Led to fetal distress, fetal death or a congenital abnormality or birth 
defect.   
 
Each AE will be assessed by the investigator to determine whether it is serious or non -
serious.  (Note:  The term serious is not synonymous with severity, which is used to 
describe the intensity of an event experienced by the subject).   
 
A serious adverse device effect  is an adverse even t that is both serious and device 
related.  
 
8.2 Potential Adverse Events (AEs)  
Potential complications associated with the investigational device  as with all other suture 
mediated closure devices may include, but are not limited to, the following:  
 
‚Ä¢ Allergic r eaction or hypersensitivity to device components  
‚Ä¢ Anemia  
‚Ä¢ Arterial stenosis/occlusion  
‚Ä¢ Arteriovenous fistula  
‚Ä¢ Bleeding/hemorrhage  
‚Ä¢ Bruising  
‚Ä¢ Death  
‚Ä¢ Deep vein thrombosis  
‚Ä¢ Device entrapment  
‚Ä¢ Device failure/malfunction/misplacement  
‚Ä¢ Diminished pulses distal t o closure site  
‚Ä¢ Embolism  
‚Ä¢ Extended Hospitalization / Delayed time to ambulation  
‚Ä¢ Hematoma  
‚Ä¢ Infection/sepsis  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 52 of 73 ‚Ä¢ Inflammation  
‚Ä¢ Intimal tear/dissection  
‚Ä¢ Ischemia distal to closure site  
‚Ä¢ Nerve injury  
‚Ä¢ Numbness  
‚Ä¢ Pain  
‚Ä¢ Perforation  
‚Ä¢ Pseudoaneurysm  
‚Ä¢ Retroperitoneal hematoma/bleeding  
‚Ä¢ Superficial vein thrombosis  
‚Ä¢ Surgical exposure/closure of common femoral artery  
‚Ä¢ Thrombus formation  
‚Ä¢ Vascular injury  
‚Ä¢ Vasovagal episode  
‚Ä¢ Vasoconstriction/vasospasm  
‚Ä¢ Wound dehiscence  
 
8.3 Follow -up of Adverse Events  
All adverse events observed from the time of enrollment throughout the duration of the study 
must be reported on the eCRF. All adverse events will be followed until resolution or 
stabilization of symptoms  through study completion  and/or the subject withdraws c onsent. 
Resolution means that the subject has returned to a baseline state of health. Stabilization 
means that the investigator does not expect any further improvement or worsening of the 
adverse event.   
 
8.4 Causality Rating  
The causal relationship of an adverse event to the investigational device will be rated as 
follows:  
 
Not Related :   An event for which an alternative explanation is conclusively identified - e.g., 
concomitant drug(s), concomitant disease(s), and/or the relationship i n time suggests that a 
causal relationship is highly unlikely.  
 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 53 of 73 Possible:   An event that is unlikely due to the use of the investigational device. An 
alternative explanation - e.g., concomitant drug(s), concomitant disease(s) - is inconclusive. 
The relatio nship in time is reasonable; therefore,  the causal relationship cannot be excluded.  
 
Probable:    An event that might be due to the use of the investigational device. An 
alternative explanation is less likely - e.g., concomitant drug(s), concomitant disease (s). The 
relationship in time is suggestive.  
 
Definitely:   An event that is due to the use of the investigational device. The event cannot be 
reasonably explained by an alternative explanation - e.g., concomitant drug(s), concomitant 
disease(s).  
 
8.5 Severity of Adverse Events  
The severity of an AE will be rated as follows:  
Mild An adverse event that is easily tolerated by the subject, causes minimal 
discomfort and does not interfere with everyday activities.  
Moderate  An adverse event that is sufficiently discomforting to interfere with normal 
everyday activities; intervention may be needed.  
Severe  An adverse event that prevents normal everyday activities; treatment or 
other intervention usually needed.  
 
 
8.6 Events Requiring Expedited Reporting  
Expedited Events refer to events that the site principal investigator sho uld report to the 
CRO/Sponsor  within twenty -four (24) hours of knowledge of the event. The appropriate 
eCRF and related documents should be completed in the data management system.  
 
If a non -serious AE becomes serious, this and other relevant follow -up in formation must 
also be reported using the appropriate eCRF.  
 
The Sponsor will immediately conduct an evaluation of any unanticipated adverse device 
effects (UADEs). If the effect is determined by the Sponsor  to present an unreasonable risk 
to the subject, all investigations or parts of the investigation presenting that risk will be 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 54 of 73 terminated as soon as possible. Termination will occur not later than five working days after 
the Sponsor  makes this determination, and not later than 15 working days after first  
receiving notice of the effect.  
 
The Sponsor  will not resume an investigation terminated under these conditions without 
an additional IRB approval.  
 
8.6.1  Expedited Events include:  
1. Unanticipated Adverse Device Effects (as defined in section 8.1) will include 
events meeting either A or B as stated below:  
A. Events meeting ALL of the following criteria:  
‚Ä¢ Not included in the list of Anticipated Events (refer to section 8.2)  
‚Ä¢ Possible, probable, or definitely related to the investigational device per 
the site principal investigator  
‚Ä¢ Serious (meets any of the following criteria):  
1. Resulted in a life -threatening illness or injury  
2. Resulted in a permanent* impairment of a body structure or body 
function  
3. Required in -patient hospitalization or prolongation of exis ting 
hospitalization  
4. Resulted in medical or surgical intervention to prevent impairment to 
body structure or a body function  
 *(Permanent means irreversible impairment or damage to a body structure or 
function, excluding trivial impairment or damage)  
B. Any o ther unanticipated serious problem associated with the investigational 
device that relates to the rights, safety, or welfare of subjects  
2. Device Failures  as defined in Section 13  
3. Device Malfunctions  as defined in Section 13  
4. User Errors:   A device is used by the investigator in a manner that is contrary 
to the IFU 
5. All Deaths  
 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 55 of 73 8.7 Clinical Events Committee (CEC)  
The CEC is composed of physicians who are interventional and/or non -interventional 
cardiologists, who are not participating in this st udy, and who do not have any investment 
with the study Sponsor. The CEC is charged with the review and classification of adverse 
events (AEs), including deaths. The CEC will establish rules outlining the minimum amount 
of data required and the algorithm fo llowed in order to classify AEs. All members of the CEC 
will meet regularly to review and classify AEs. All appropriate data will be reviewed by the 
CEC. The CEC will forward a report of event reviews and classifications as outlined in the 
CEC charter.  
 
8.8 Data and Safety Monitoring Board (DSMB)  
The DSMB will be appointed to monitor the conduct of the study and subject safety by 
periodically reviewing data from the study. The DSMB will oversee the overall safety of 
current and future study subjects by protecti ng them from avoidable harm. The DSMB will 
review adverse events and other relevant study data and will recommend study t ermination 
if safety concerns warrant such action. The DSMB will also establish guideline criteria for 
recommen ding study termination, to the extent possible that the DSM B can predict adverse 
events or outcomes, before the propos ed study begins.  
 
The DSMB will be an independent committee with no direct involvement in the day -to-day 
undertaking of the study and no investment i n the Sponsor. DSMB members and activities 
may overlap with the CEC as appropriate. The DSMB will consist of physicians, including 
one chairperson and a statistician who will provide an independent review of the data. The 
physicians will include an interve ntional cardiologist and vascular surgeon experienced in 
vascular closure to ensure appropriate review of vascular complications in the study. The 
DSMB report will detail all serious and unexpected adverse events or other unanticipated 
problems that involv e potential risk to future study participants. If the DSMB has concerns 
regarding the study, the DSMB will notify the Sponsor, who will provide the relevant 
summaries to local IRBs. Actions taken by any IRB in response to safety concerns will be 
reported t o the DSMB.  
 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 56 of 73 The DSMB will meet periodically throughout the study in order to assure close and timely 
monitoring of adverse events and outcomes. The operational details of the DSMB will be 
determined early in the study and formalized in the DSMB Charter.  
The Sponsor and/or CRO will be responsible for working with the DSMB to ensure the 
DSMB Charter is developed. After the DSMB Charter has been finalized and approved by 
the DSMB, any changes or deviations to the plans in the charter will be documented in t he 
minutes of the DSMB meetings.  
 
Reports will be prepared by the Sponsor and/or CRO as requested by the DSMB Chairman 
and as required per the charter. In addition to safety data, the reports may include 
recruitment and retention rates, interim analyses a nd other information as requested by the 
DSMB Chairperson.  
 
9 Risk Assessment  
 
9.1 Risk Management Procedure  
Subjects will be monitored closely throughout the study duration. Risks will be further 
mitigated through selection of qualified physicians, appropriate training, and study 
monitoring ensured by the following:  
‚Ä¢ Investigators who participate in the study will be experienced and skilled in  
endovascular techniques. Additionally, investigators, in conjunction with the  
investigational site, will have  adequate resources for participation in a clinical  
study.  
‚Ä¢ The study has been designed to ensure treatment and follow -up of subjects are 
consistent with current medical practice.  
‚Ä¢ Each investigator will ensure oversight and approval of the study by their IRB prior to 
initiation of the clinical study at his/her investigational site.  
‚Ä¢ The investigator and study personnel will be trained on the clinical protocol and IFU 
for the investigational device.  
‚Ä¢ Subjects will be carefully evaluated against the elig ibility criteria prior to entering the 
clinical study to ensure that their diagnosis and medical status are appropriate for 
participation.  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 57 of 73 ‚Ä¢ Subjects will be monitored throughout the follow -up period as defined in the study 
protocol. Subjects will have visit s with the investigator or his/her designee to monitor 
the subjects‚Äô status  pre-procedure, intra -procedure, and post -procedure . 
‚Ä¢ A DUS will be performed at 30 days post -procedure and repeated at 60 days if 
subject had an abnormal 30 day ultrasound to ensure  adequate evaluation of the 
target limb access site . 
 
9.2 Potential Benefits  
Subjects enrolled in this clinical study  will be monitored closely throughout the study and 
have regular assessments according to the investigator ‚Äôs standards of care . The data 
collec ted during the clinical study will provide further  understanding how the Cross -SealTM 
System  is clinically beneficial. Potential benefits may include:  
‚Ä¢ Reduced Time -to-Ambulation (TTA)  
‚Ä¢ Reduced Time -to-Hemostasis (TTH)  
‚Ä¢ Improved quality of life  
 
10 Centers for Medicare and Medicaid Services (CMS) Reimbursement  
The Sponsor will seek applicable Medicare coverage in compliance with CMS requirements 
for this study. Based on the target study population including mean age, approximately 
70% of subjects enr olled in this study will utilize CMS/Medicare reimbursement during their 
participation.   
 
The study will be conducted in compliance with all applicable Federal regulations concerning 
the protection of human subjects found at 21 CFR parts 50, 56, and 812, and 45 CFR part 
46. In addition, the study will be registered with the National Institutes of Health National 
Library of Medicine‚Äôs ClinicalTrials.gov.  
 
The Sponsor has a legal responsibility to the regulatory authorities to fully report all results 
of sp onsored clinical studies. No investigat ional  procedures other than those in this protocol 
shall be undertaken. The sponsor intends to submit a formal report to FDA following 
completion of the last subject visit required for primary endpoint analysis. Shoul d the study 
be terminated early, the Sponsor will make every effort to expedite reporting of study 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 58 of 73 results to the FDA database for public review. Any use of the investigational device by an 
investigator that is contradictory to the application described in  the IFU will be categorized 
as device misuse.  
 
11 Monitoring  
The Sponsor will perform monitoring functions within this clinical study  and may be 
delegated to a CRO designate as needed . Study  monitors will work in accordance with 
standard operating procedures (SOPs) and the approved Monitoring Plan. Any CRO 
monitors have the same rights and responsibilities as monitors from the Sponsor 
organization.  
 
At the site, monitors will perform and ver ify the following:  
‚Ä¢ The adequacy and experience of the study center  including Sponsor notification of 
any problems relating to facilities, technical equipment or medical staff  
‚Ä¢ Written Informed Consent has been obtained from all subjects prior to any study 
related procedures being performed and that data is recorded correctly and 
completely  
‚Ä¢ Source Document Verification (SDV):  c omparing data in the  eCRFs  to ensure they  
correspond with applicable  source data, and to inform the Sponsor and investigator 
of any discrepancies, errors or omissions  
‚Ä¢ Ensure a dherence to the protocol and applicable regulations  at the investigational 
site and notify the Sponsor promptly of any deviations  
‚Ä¢ Evaluate s ubject compliance and support subject retention efforts at the sit e 
‚Ä¢ Device  accountability and appropriate storage conditions are maintained according 
to the IFU   
 
Data will be collected using eCRFs for this study. Investigative sites will enter data directly 
into the eCRFs via a web -based system. A Sponsor representativ e will provide training and 
technical assistance to the investigator and site staff on the procedural application, intended 
use, and performance characteristics of the investigational device.  In addition, a Sponsor 
representative will schedule periodic, on -site visits to observe clinical procedures, under 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 59 of 73 supervision of the investigator, and to answer questions or concerns regarding the 
investigational device.  
 
Given that on -site monitoring at some trial locations may be impacted due to the COVID -19 
pandemic, the Sponsor has implemented both central and remote monitoring to maintain 
oversight of  the clinical study and sites. This includes, but is not limited to, telephone and/or 
email contacts with the sites (to review study procedures, trial  participant status, and study 
progress), remote review of de -identified source, remote access to electronic medical 
records (EMR), and frequent eCRF reviews.  Given the ongoing and unpredictable nature of 
the COVID -19 pandemic, individual site variability  on permitting remote EMR and/or the 
transmission of de -identified source, as well as continually changing local and state 
mandates governing travel, the Sponsor may have to adapt its monitoring processes 
regularly to fulfill its obligations as a Sponsor u nder federal law and regulations.  The 
Sponsor will continuously assess each site and will monitor study data at the earliest 
possible opportunity, either in person or remotely.  
 
12 Image Analysis  
Duplex Ultrasound (DUS) of the femoral artery will be obtaine d at 30 days post -procedure 
(target limb only). In the instance of an abnormal DUS at 30 days, the subject will be 
required to conduct a repeat DUS at 60 days post -procedure.  
 
All Duplex Ultrasound images obtained during the study will be anonymized and s ent to a 
central core laboratory for independent analysis.  
 
13  Device Failure  and Malfunction  
A device failure has occurred when the device is used in accordance with the IFU, but does 
not perform as described in  the IFU , and also negatively impacts treatme nt of the study 
subject . Device Failures may include the following:    
‚Ä¢ Device used in study subject resulting in the occurrence of a major complication  
‚Ä¢ Unable to use RESET 1 Button  
‚Ä¢ Unable to deploy PLUNGER on device  
‚Ä¢ Unable to use RESET 2 Button  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 60 of 73  
A device malfunction occurs when the device is used in accordance with the IFU and an 
unexpected change to the device contradictory to the IFU is observed, which may or may 
not affect device performance . Device Malfunctions may include the following : 
‚Ä¢ Device(s) with which insertion attempts were made, but was not used in the 
subject . 
‚Ä¢ Unable to observe bleeding back after sufficient dissection is performed  
‚Ä¢ Unable to deploy slider of Cross -SealTM Device  
‚Ä¢ Needle dislodged after device deployment  
‚Ä¢ Unable to cut suture with Suture Trimmer  
‚Ä¢ Device is damaged in packaging  
‚Ä¢ Issues with use of Knot Tyer and/or Knot Pusher  
‚Ä¢ Suture break during device, Knot Tyer and/or Knot Pusher use  
‚Ä¢ Device packaging issue  
‚Ä¢ Device Sterility issue  
 
Device malfunctions occurri ng in roll -in subjects will be additionally evaluated  for potential 
relationship with the learning curve of the investigational device (e.g., operator applies 
excess tension to suture during pre -closure causing break)  
 
In the case where a device has  malfunctioned/failed, the i nvestigator must make every 
possible effort to return the device to the Sponsor , unless there is a known contamination 
with an infectious disease (i.e. Hepatitis B, C or HIV).  
 
14 Statistical Methods  
14.1 Sample Size  Determination  
The sample size calculations were performed using PASS 2020 Version 20.0.2iii.  The 
appendix included the output from the software.  The sample size for the study is based 
on power considerations for the primary effectiveness endpoint. As will be described 
below, this sample size should also provide adequate power for the primary safety 
endpoint.  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 61 of 73 14.1.1  Primary Efficacy Endpoint  
The primary effectiveness hypothesis will be tested by comparing the primary 
effectiveness endpoint, mean time -to-hemostasis (TT H), against a performance goal 
(PG) of 15 minutes.  
The comparison to the performance goal will be based on the following statistical 
hypothesis test:  
ùêªùëÇ: ùúáùëáùëáùêª   ‚â• 15 
ùêªùê¥: ùúáùëáùëáùêª   < 15 
where ùúáùëáùëáùêªis the mean time -to-hemostasis in  minutes.  
The test will be based on whether the upper one -sided 97.5% confidence limit (based on 
a t-distribution)iv is less than 15. Assuming similar performance to Perclose ProGlide¬Æ, 
with a mean time -to-hemostasis of 9.8 minutes and a standard deviation of 17 minutes 
the sample sizes for power levels from 80 to 90%  
a Table 3: Primary Efficacy Endpoint Sample Sizes for Various levels of Power  
Power  Sample Size  Maximum Observed Time 
(minutes) and still reject H 0 
80.0%  86 10.8 
81.4%  89 10.9 
82.3%  91 10.9 
83.1%  93 10.9 
84.3%  96 11.0 
85.0%  98 11.1 
Successful rejection of the null hypothesis will mean that the PG has been met.  
 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 62 of 73 14.1.1.1  Development of the Performance Goal  
The PG was derived from literature for the Perclose ProGlide¬Æ (Abbott Vascular, Inc., 
Redwood City, CA, USA), a suture -mediated device indicated for the closure of large 
arterial access sites.  
14.1.2  Primary Safety Endpoint  
The primary safety hypothesis will be tested by comparing the primary safety endpoint, 
freedom from major complications of the target limb access site within 30 days post -
procedure, against a performance goal.   
The comparison to the performance goal will be based on the following statistical 
hypothesis test:  
ùêªùëÇ: ùëù ‚â§ 85.2%  
ùêªùê¥: ùëù > 85.2%  
where p is the safety endpoint rate for the test device.  
Assuming similar performance as ProGlide (an event -free rate of 94%), one -sided alpha 
= 0.05, the sample sizes for various levels of power are:  
Table 4: Primary Safety Endpoint Sample Sizes for Various levels of Power  
Power  Sample Size  Minimum # of Event Free 
Patients needed to reject the 
H0 
81.3%  78 72 
85.6%  86 79 
88.3%  95 87 
 
14.1.2.1  Development of the Performance Goal  
The observed rate of major complications for ProGlide was 6% (3/50), with a one -sided 
exact binomial upper 95% confidence bound of 14.8%. In terms of an event -free rate, 
these quantities are mathematically equivalent to an observed event -free rate of 94% 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 63 of 73 with a lower confidence boun d of 85.2%. Accordingly, for the current study, a value of 
85.2% is proposed for a performance goal for the primary safety endpoint based on the 
event -free rate.  
14.2 Statistical  Analyses  
 
14.2.1  General  Considerations  
Except where otherwise specified, the following g eneral principles apply to the planned 
statistical analyses. All statistical analyses will be conducted using {SAS version 9.3 or 
later (SAS Institute Inc., Cary, NC)} or other widely accepted statistical or graphical 
software as required.  
14.2.1.1  Descriptive Statistics  
Continuous data will be summarized with mean, standard deviation, median, minimum, 
maximum, and number of evaluable observations. Categorical variables will be 
summarized with frequency counts and percentages. Confidence intervals may be 
presented, where appropriate, using the t -distribution for continuous data and exact 
binomial method for categorical variables.  
14.2.1.2  Study  Visit  
Study visit Day 0 is the date of the index procedure. Day in the study will be calculated 
relative to the index procedure as follows:  
Study Day = Assessment Date ‚Äì Index Procedure Date  
Each subject duration in the study will be based on the last study contact date, which is 
the latest date of all follow -up visits, assessments, adverse event onset or res olution, 
and study exit, including date of death.  
Duration will be calculated as follows: Duration Days = Start Date ‚Äì End Date  
14.2.1.3  Visit Windows  
Unless otherwise specified, visit assessments will be analyzed for each analysis time 
point according to the visit  entered in the electronic Case Report Form (eCRF).  
14.2.1.4  Statistical  Significance  
Unless otherwise specified, hypothesis testing will be performed at the two -sided 0.05 
significance level. P -values will be rounded to three decimal places. If a p -value is less 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 64 of 73 than 0.001 will be reported as "<0.001". If a p -value is greater than 0.999, it will be 
reported as ">0.999".  
14.2.1.5  Reporting Precision  
Unless otherwise specified, the following conventions will apply for data display. In 
general, percentages will be displayed to  1 decimal place. Percentages <0.05% will be 
reported to 2 decimal places. For continuous parameters, means and medians will be 
reported to 1 additional decimal place than the measured value. In contrast, the standard 
deviation will be reported to 2 additi onal decimal places than the measured value. 
Minimum and maximum values will be reported to the same precision as the measured 
value.  
14.2.2  Analysis  Populations  
14.2.2.1  Full Analysis Set  
The full analysis set (FAS) as defined by the ICH E9v as "The set of subjects that  is as 
close as possible to the ideal implied by the intention -to-treat principle." The guideline 
also defined the Intention -To-Treat Principle as the effect of a treatment policy can be 
best assessed by evaluating based on the intention to treat a subject  (i.e., the planned 
treatment regimen) rather than the actual treatment given.  Therefore, the FAS includes 
all patients that were consented, enrolled, and met the inclusion/exclusion criteria.  
14.2.2.2  Per-Protocol Analysis Set  
The protocol definition of the TTH e ndpoint includes only those patients that received the 
test device and did not have adjunctive therapy other than light compression applied to 
the access site manually, with a dressing, or as per the investigator's standard procedure 
for suture -mediated cl osure devices.  Therefore, the per -protocol analysis set (PPS) 
includes those patients in the FAS where the patient received the test device and did not 
have adjunctive therapy other than light compression.  
14.2.2.3  Full Roll -In Analysis Set  
The full roll -in analy sis set (FAS_RI) are those patients that meet the same criteria as the 
FAS but are identified as roll -in patients.  
14.2.2.4  Per-Protocol Roll -In Analysis Set  
The per -protocol roll -in analysis(PPS_RI) set are those patients that meet the same 
criteria as the PPS but  are identified as roll -in patients.  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 65 of 73 14.2.2.5  Efficacy Analysis Set  
Due to the challenges during the pandemic, the number of patients in a non -missing 
primary efficacy endpoint may drop below the lowest accepted power (80%) for approval 
trial design (< 86 patients).  If the number of patients in the PPS is <= 86, the efficacy 
analysis set will include the patients in the PPS and the last 18 sequentially enrolled 
patients from the PPS_RI.  If the number of patients in the PPS is > 86, then the efficacy 
analy sis set will only include PPS patients.  
14.2.2.6  Safety Analysis Set  
Due to the challenges during the pandemic, the number of patients in a non -missing 
primary safety endpoint may drop below the lowest accepted power (80%) for approval 
trial design (< 78 patients).  If the number of patients in the FAS is <= 78, the safety 
analysis set will include the patients in the FAS and the last 18 sequentially enrolled 
patients from the FAS_RI.  If the number of patients in the FAS is > 78, then the safety 
analysis set will on ly include FAS patients.  
14.2.3  Poolability  Analyses  
All investigational sites will follow the requirements of a common protocol and 
standardized  data collection procedures and forms. The primary endpoints will be 
presented separately (major  and minor complications will be presented separately for the 
primary safety endpoint) for each site using descriptive statistics. Poolability of the 
primary endpoints across the investigational site will be evaluated using a regression 
model with fixed eff ects for the site using the FAS for the primary safety endpoint and 
PPS for primary efficacy endpoint. Sites enrolling less than five subjects will be 
combined with the geographically nearest site. If the p -value for the site effect is <0.15, 
additional ex ploratory analyses will be performed to understand any variations in 
outcomes by site.  
14.2.4  Handling of Missing  Data  
All attempts will be made to limit the amount of missing data. For all analyses of the 
primary endpoints, the number of observations available, patients with no primary safety 
endpoint information, and patients with imputed results will be reported so the reader can 
assess the impact of missing data.  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 66 of 73 14.2.5  Imputation for Endpoints  
Due to the challenges related to the COVID -19 pandemic faced during the e nrollment, 
some 30 -day follow -up visits were outside of the protocol specified window.  Therefore, 
for those patients whose 30 -day visit was outside the window, the primary safety 
endpoint will be imputed based on the on visits that occurred at a minimum o f 23 days 
post-discharge and is the closest to the 30 -day visit. If there were no post -discharge 
visits, the primary safety endpoint will be imputed based on the site contacting the 
patient by phone as well as reviewing their records to determine the patie nt's primary 
safety endpoint status at 30 days. If even that information is not available, then the 
patient will be considered as missing the primary safety endpoint data.  
14.2.6  Sensitivity Analyses  
Sensitivity analyses will be performed to assess the impact of missing data for the 
primary safety endpoint; a tipping point analysis will be conducted in which subjects 
censored without a 30 days follow -up visit are sequentially imputed as failures at the 
time of  censoring. The primary safety endpoint analysis will be repeated after each 
sequentially imputed failure.  
Sensitivity analyses will be performed to assess the impact of missing data for the 
primary efficacy endpoint; a tipping point analysis will be conducted in which subjects 
without a TTH are  sequentially imputed as 15 minutes (the performance goal). The 
primary efficacy endpoint analysis will be repeated after each sequentially imputed 
value.  
14.2.7  Imputation for Dates  
More generally, in the case of partial adverse event onset date or date of death , the 
unknown portion of the date of the event will be imputed. If the month and year are 
known, the 15th of the month will be used for analysis. If only the year is known, the 
event will be analyzed as if it occurred on June 30th of the known year. In the  rare case 
that the date is fully unknown, the date will be imputed as the index procedure date. 
Imputation of partial dates is subject to the condition that it must occur on or after the 
index procedure date. In the case where the imputed date is before t he index procedure 
date, the date of the index procedure will be used. As death cannot occur before any 
documented subject contact, for date of death, the imputed date of death must occur on 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 67 of 73 or after the last known contact in the study.  
14.2.8  Subject  Disposition  
Subjects who are screened and signed an informed consent form, but do not meet all 
protocol eligibility criteria (i.e., screening failure), will be excluded from the statistical 
analyses. These subjects will be summarized in a subject accountability table  only.  
Subject accountability will be summarized by visit for those in the FAS.  The number of 
subjects who are enrolled, eligible for follow -up, and number completing clinical follow -up 
will be summarized for each protocol -required  visit. 
14.2.9  Demographics and Baseline  Characteristics  
Descriptive statistics will be presented for clinically relevant baseline demographic, 
medical history, and clinical characteristic variables.  
14.2.10  Analysis of Study  Endpoints  
Study success is defined as the successful rejection of the corresponding null 
hypotheses for each of the primary safety and effectiveness endpoints.  
14.2.10.1  Primary Efficacy  Endpoint  
The primary efficacy endpoint will be evaluated using the using the efficacy analysis set.  
The mean and standar d error will be reported for the primary efficacy endpoint.  A one -
sample t -distribution will be used for calculating the upper 97.5% confidence limit.   
14.2.10.1.1  Sensitivity Analyses  
There will be three sensitivity analyses:  
1. The primary efficacy endpoint analysis will be repeated with the PPS patients only if 
PPS_RI patients are added to the efficacy analysis set  
2. Tipping analysis based on missing data in the efficacy analysis set as described in 
section 14.2.6  
3. The primary efficacy endpoint analysis will be repeated with the PPS_RI and the 
efficacy analysis set combined.  
14.2.10.2  Primary Safety Analysis  
The primary safety endpoint will be evaluated using the FAS or the safety analysis set if 
roll-ins are needed.  The endpoint will be presented as the proportion of subjects with 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 68 of 73 freedom from primary safety endpoint and the lower 95% confidence limit using the 
Clopper -Pearson exact methodvi.  If the one -sided 95% confidenc e limit is greater than 
85.2%, then the device will have met the performance goal for safety.  
14.2.10.2.1  Sensitivity Analyses  
There will be three sensitivity analyses:  
1. The primary safety endpoint analysis will be repeated with the FAS patients only if 
FAS_RI patients  are added to the safety analysis set  
2. Tipping analysis based on missing data in the safety analysis set, as described in 
section 14.2.6 . 
3. The primary efficacy endpoint analysis will be repeated with the FAS_RI and the 
safety analysis set combined.  
14.2.10.3  Secondary Endpoints  
No formal hypothesis tests for the secondary and exploratory endpoints will be 
performed; endpoints will be summarized using the FAS with descriptive statistics.  
14.2.11  Subgroup  Analyses  
Subgroup analysis of the primary safety (major and minor complications analyzed 
separately) and efficacy endpoints will be performed for the following subgroups: gender, 
age (Age<65, Age‚â•65), and race (whi te vs. non -white). These analyses are intended to 
assess the consistency of results across subgroups.  
Subgroup analyses will be performed using the efficacy analysis set for the primary 
efficacy endpoint and the safety analysis set for the primary safety e ndpoint. For each 
subgroup, a regression model will be fit that includes fixed effects for subgroup 
membership.  
14.2.12  Interim  Analyses  
There are no formal plans for interim analyses for the purposes of early stopping for 
effectiveness or sample size adjustments . Interim safety reports will be performed as 
requested by the DSMB Charter. Unless otherwise specified, methods for such reports 
may follow those outlined in this document.  
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 69 of 73 14.2.13  Protocol  Deviations  
Investigational sites will report deviations from the procedur es outlined in the CIP on the 
eCRF. Protocol deviations will be summarized for all deviations and by type with event 
counts and number of subjects with at least one deviation.  
14.2.14  Additional Changes to Planned  Analyses  
Any additional changes to planned statistical analyses determined necessary before 
performing the analyses will be documented in an amended Statistical Analysis Plan 
Version 1.4 and approved before the analysis when possible. Any other deviations or 
changes from the planned analyses deemed  necessary due to violation of critical 
underlying statistical assumptions, data characteristics, or missing data will be clearly 
described in the clinical study report with justification and rationale.  
15 Reporting  
A final integrated clinical/statistical report will be prepared  and provided to the FDA for the 
purposes of fulfilling the requirements of the IDE and PMA submission.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 70 of 73 Append ix 1 References  
 
1. World Health Organization website. http://www.who.int/cardiovascular_diseases  
2. Bechara CF, Annambhotla S, Lin PH. Access site management with vascular closure devices 
for percutaneous transarterial procedures. J. Vasc. Surg . 2010;52(6):1682 -1696.  
3. Why population aging matters: a global perspective. National Institute on Aging.  
https://2001 -2009.state.gov/g/oes/rls/or/81537.htm  
4. Haulon S, Hassen Khodja R, Proudfoot CW, Samuels E. A systematic literature review of the 
efficacy and safety of the Prostar XL device for the closure of large femoral arterial access sites 
in patients undergoing percutaneous endovascular aortic procedu res. Eur. J. Vasc. Endovasc. 
Surg . 2011;41(2):201 -13. 
5. Patel MR, Jneid H, Derdeyn CP, et al. Arteriotomy closure devices for cardiovascular 
procedures: a scientific statement from the American Heart Association. Circulation  
2010;122(18):1882 -93. 
6. Tavri s DR, Wang Y, Jacobs S, et al. Bleeding and Vascular Complications at the Femoral 
Access Site Following Percutaneous Coronary Intervention (PCI): An Evaluation of Hemostasis 
Strategies. J Invasive Cardiol  2012;24(7):328 -334. 
7. Leon MB, Smith CR, Mack M, e t al. Transcatheter aortic -valve implantation for aortic stenosis 
in patients who cannot undergo surgery. NEJM . 2010;Vol. 363(17):1597 -1607.  
8. Salinas P, Moreno R, Lopez -Sendon JL. Transcatheter aortic valve implantation: Current 
status and future perspec tives. World J. Cardiol . 2011;3(6):177 -85. 
9. Hui DS, Shavelle DM, Cunningham MJ, Matthews RV, et al. Contemporary use of Balloon 
Aortic Valvuloplasty in the era of transcatheter aortic valve implantation. Tex Heart Inst J  
2014;41(5):469 -76. 
10. Pedersen W R, Goldenberg IF, Feldman TE. Balloon aortic valvuloplasty in the TAVI era. A 
review of current technique and uses in stand -alone, bridging, and predilation settings. Cardiac 
Interventions Today  2012; July/August:77 -84. 
11. Otto CM, Mickel MC, Kennedy JW, et al. Three year outcome after balloon aortic  
valvuloplasty: insights into prognosis of valvular aortic stenosis. Circulation . 1994;89:642 -650. 
12. Kogoj P, Devjak R, Bunc M. Balloon aortic valvuloplasty (BAV) as a bridge to aortic valve 
replacement in ca ncer patients who require urgent non -cardiac surgery. Radiol Oncol  2014; 
48(1): 62 -66. 
13. Nwaejike N, Mils K, Stables R, et al. Balloon aortic valvuloplasty as a bridge to aortic valve 
surgery for severe aortic stenosis. Interactive CardioVascular and Tho racic Surgery  20 (2015) 
429‚Äì435. 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 71 of 73 14. Dencker D, Taudorf, M, Luk V, et al. Frequency and effect of access -related vascular injury 
and subsequent vascular intervention after transcatheter aortic valve replacement. Am J Cardiol  
2016;118(8):1244 -1250.  
15. Barb anti M, Capranzano P, Ohno Y, et al. Comparison of suture -based vascular closure 
devices in transfemoral transcatheter aortic valve implantation. EuroIntervention  2015;11:690 -
697. 
16. Holper, EM, Kim RJ. Mack M, et al. Randomized trial of surgical cutdown versus  
percutaneous access in transfemoral TAVR. Cathet Cardiovasc Intervent.  2014, 83: 457 ‚Äì464. 
17. Ando T, Briasoulis A, Holmes AA, et al. Percutaneous versus surgical cut -down access in 
transfemoral transcatheter aortic valve replacement: A meta -analysi s, J Card Surg , 2016, 
Dec;31(12):710 ‚Äì717. 
18. Jackson SR, Chang DC, Freischlag JA. Comparison of Long -term Survival After Open vs 
Endovascular Repair of Intact Abdominal Aortic Aneurysm Among Medicare Beneficiaries. 
JAMA . 2012;307(15):1621 -1628.  
19. Scherm erhorn, Marc. "Endovascular vs. open repair of abdominal aortic aneurysms in the 
Medicare population. NEJM . 2008;358 (5): 464 ‚Äì74. 
20. El -Sayed H, Ramiawi B. The current status of endovascular repair of thoracic aortic 
aneurysms (TEVAR). Methodist Debakey Cardiovasc J . 2011;7(3):15 -9. 
21. Turi ZG. Overview of Vascular Closure. Endovasc. Today  2010;(May).  
22. Vascular A. Summary of safety and effectiveness data (SSED): Perclose ProGlide 6F 
Suture -Mediated Closure System. PMA: P960043/S80 .; 2013:1 -16. 
23. Meh illi J, Jochheim D, Abdel -Wahab M, et al. One -year outcomes with two suture -mediated 
closure devices to achieve access -site haemostasis following transfemoral transcatheter aortic 
valve implantation. EuroIntervention . 2016 Nov 20;12(10):1298 -1304.  
24. Nels on PR, Kracjer Z, Kansal N, et al. A multicenter, randomized, controlled trial of totally 
percutaneous access versus open femoral exposure for endovascular aortic aneurysm repair 
(the PEVAR trial). J Vasc Surg . 2014 May;59(5):1181 -93. 
25. Seeger J, Gonska B, Rodewald C, et al. Impact of suture mediated femoral access site 
closure with the Prostar XL compared to the ProGlide system on outcome in transfemoral aortic 
valve implantation. Int J Cardiol.  2016 Nov 15;223:564 -567. 
26. Saleh N, De Palma R, Settergre n M, et al. Femoral access -related complications during 
percutaneous transcatheter aortic valve implantation comparing single versus double Prostar XL 
device closure. Catheter Cardiovasc Interv . 2015 Dec 1;86(7):1255 -61. 
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 72 of 73 27. Thomas C, Steger V, Heller S, et al. Safety and Efficacy of the Prostar XL Vascular Closing 
Device for Percutaneous Closure of Large Arterial Access Sites. Radiol. Res. Pract.  
2013;2013:875484.  
28. Kodama A, Yamamoto M, Shimura T, et al. Comparative da ta of single versus double 
proglide vascular preclose technique after percutaneous transfemoral transcatheter aortic valve 
implantation from the optimized catheter valvular intervention (OCEAN -TAVI) japanese 
multicenter registry. Catheter Cardiovasc Interv . 2016 Oct 27. doi: 10.1002/ccd.26686.  
29. Pratesi G, Barbante M, Pulli R, et al. Italian Percutaneous EVAR (IPER) Registry: outcomes 
of 2381 percutaneous femoral access sites' closure for aortic stent -graft. J Cardiovasc Surg  
(Torino). 2015 Dec;56(6):889 -98. 
30. van Dorp M, Ruyssers M, Amajoud Z, et al. Preclose Percutaneous Endurant‚Ñ¢ Endografting 
with the Proglide‚Ñ¢ Device: a Safe and Feasible Combination. Acta Chir Belg.  2015 May -
Jun;115(3):219 -23. 
31. Ichihashi T, Ito T, Kinoshita Y, et al. Safety and ut ility of total percutaneous endovascular 
aortic repair with a single Perclose ProGlide closure device. J Vasc Surg.  2016 Mar;63(3):585 -8. 
32. Griese DP, Reents W, Diegeler A, et al. Simple, effective and safe vascular access 
siteclosure with the double -ProGlide preclose technique in 162 patients receiving transfemoral 
transcatheter aortic valve implantation. Catheter Cardiovasc Interv . 2013 Nov 1;82(5):E734 - 
33. Hu G, Chen B, Fu W, et al. Predictors and Treatments of Proglide -Related Complications in 
Percut aneous Endovascular Aortic Repair. PLoS ONE  2015 10(4):e0123739. doi:10.1371.  
34. Rijk√©e MP, Statius van Eps RG, Wever JJ, et al. Predictors of Failure of Closure in 
Percutaneous EVAR Using the Prostar XL Percutaneous Vascular Surgery Device. Eur J Vasc 
Endovasc Surg . 2015 Jan;49(1):45 -9. 
35. Vidi VD MM et al. Vascular Closure Device Failure in Contemporary Practice. JACC. 
Cardiovasc. Interv . 2012;5(8):837 -844. 
36. PASS 14 Power Analysis and Sample Size Software (2015). NCSS, LLC Kaysville, Utah, 
USA. ncss. com/software/pass . 
 
i PASS 2020 Power Analysis and Sample Size Software (2020). 
NCSS, LLC. Kaysville, Utah, USA, ncss.com/software/pass.  
ii Dawson, B., & Trapp, R. G. (2004). Basic & clinical 
biostatistics (4th ed.) . New York: Lange Medical Books -McGraw-
Hill, chapter 5  
iii PASS 2020 Power Analysis and Sample Size Software (2020). 
NCSS, LLC. Kaysville, Utah, USA, ncss.com/software/pass.   
Clinical Investigational Plan  
Cross -SealTM IDE Trial  
Protocol Number:  TIS2018 -01  
Version 1.3 
 
 
 
30 Oct 2018                                          CONFIDENTIAL  Page 73 of 73  
iv Dawson, B., & Trapp, R. G. (2004). Basic & clinical 
biostatistics (4th ed.) . New York: Lange Medical Books -McGraw-
Hill, chapter 5  
v International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use 
(1998), ICH Harmonised Tripartite Guideline Statistical 
Principles For Clinical Trials E9 , retrieved from 
https://database.ich.org/sites/default/files/E9_Guideline.pdf  
vi Clopper, C.; Pearson, E. S. (1934). The use of confidence or 
fiducial limits illustrated in the case of the binomial. 
Biometrika . 26 (4): 404 ‚Äì413. doi:1 0.1093/biomet/26.4.404.  